data_5gsf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5gsf _Structure_validation_residue.Date_analyzed 2017-01-20 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 CA--C 1.54 0.596 0 CA-C-O 119.402 -0.332 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.48 HH12 ' ND2' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.606 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.606 HG13 ' O ' ' A' ' 6' ' ' GLY . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.693 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.48 ' ND2' HH12 ' A' ' 4' ' ' ARG . 0.3 OUTLIER -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.67 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.67 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.603 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.468 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.439 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.439 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.509 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.514 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.603 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.541 0.612 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.534 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.582 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.548 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.463 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.548 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.2 p-10 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.443 ' H ' HD21 ' A' ' 17' ' ' ASN . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.631 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.463 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.457 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG21 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.562 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.582 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.474 0.726 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.641 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.641 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.468 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.497 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.434 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.434 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.468 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.578 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.7 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.433 ' H ' HD21 ' A' ' 17' ' ' ASN . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.497 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.502 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.567 ' O ' HD11 ' A' ' 25' ' ' ILE . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.454 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.539 0.54 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' ND2' ' A' ' 17' ' ' ASN . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.496 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.582 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.582 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.798 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.417 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.417 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.798 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.508 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 17.9 m-20 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.496 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.508 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.413 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.433 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.433 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.559 HG22 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.486 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.419 ' O ' HD12 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.788 HD13 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.762 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.567 HG22 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.891 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.614 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.626 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.891 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.673 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.451 ' N ' HD21 ' A' ' 17' ' ' ASN . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.673 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.597 HD12 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.483 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.483 HG21 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.788 ' SG ' HD13 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.597 ' OXT' HD12 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.69 HD13 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp . . . . . 0 CA--C 1.545 0.754 0 CA-C-O 119.175 -0.441 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.723 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.512 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.536 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.69 ' SG ' HD13 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 2' ' ' ILE . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.488 HD21 ' N ' ' A' ' 18' ' ' SER . 0.6 OUTLIER -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.488 ' N ' HD21 ' A' ' 17' ' ' ASN . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.713 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.512 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.553 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.723 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.713 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.556 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt . . . . . 0 CA--C 1.539 0.534 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 26' ' ' CYS . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.52 HD11 ' O ' ' A' ' 7' ' ' ILE . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.518 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.412 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.454 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.454 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.42 ' O ' HD23 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.556 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.615 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.408 ' H ' ' HB2' ' A' ' 17' ' ' ASN . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.412 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.513 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 25' ' ' ILE . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.808 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.423 ' HB1' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.467 0.398 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.415 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.43 ' H ' ' H ' ' A' ' 26' ' ' CYS . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.692 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.4 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.409 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.557 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.519 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.557 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.564 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.533 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.409 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.412 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.564 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.651 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.651 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.608 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.461 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.441 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.441 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.608 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.586 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.492 ' N ' HD21 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.789 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.461 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.638 ' O ' HD12 ' A' ' 25' ' ' ILE . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.789 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.488 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.1 pt . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 119.507 -0.283 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.663 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.755 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.551 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.47 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.488 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.434 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.745 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.745 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.551 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.428 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.538 ' C ' HG23 ' A' ' 7' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.755 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB2' ' HE ' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.564 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt . . . . . 0 CA--C 1.538 0.496 0 CA-C-O 119.6 -0.238 . . . . 0.0 111.302 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.452 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.452 HD11 ' C ' ' A' ' 6' ' ' GLY . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.402 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.734 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.472 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.734 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.468 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.468 HD13 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.468 ' OXT' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.448 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.623 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.429 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.449 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.449 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.41 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.448 ' H ' HD21 ' A' ' 17' ' ' ASN . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.596 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.429 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.589 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.448 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.502 0 CA-C-O 119.425 -0.322 . . . . 0.0 110.364 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.658 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.658 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.473 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.42 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.735 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.735 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.42 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.471 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.634 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.484 ' O ' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.539 0.55 0 CA-C-O 119.145 -0.455 . . . . 0.0 110.412 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.629 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.629 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.457 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.424 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.424 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.442 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.731 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.457 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.553 ' O ' HD11 ' A' ' 25' ' ' ILE . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.672 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.632 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt . . . . . 0 CA--C 1.542 0.644 0 CA-C-O 119.433 -0.318 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.467 ' C ' HD13 ' A' ' 7' ' ' ILE . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.41 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.632 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.659 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.659 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.448 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.41 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.563 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.621 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.448 ' HB1' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.705 HD11 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 119.13 -0.462 . . . . 0.0 110.336 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.441 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 12' ' ' LEU . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 14' ' ' GLY . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.424 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.705 ' SG ' HD11 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.439 ' H ' HD21 ' A' ' 17' ' ' ASN . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.481 HD13 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.406 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.424 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.456 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.481 ' OXT' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.467 HD12 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 119.679 -0.2 . . . . 0.0 111.13 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.63 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.63 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.666 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.42 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.666 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.589 ' ND2' ' H ' ' A' ' 18' ' ' SER . 1.9 p-10 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.589 ' H ' ' ND2' ' A' ' 17' ' ' ASN . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.453 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.56 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.598 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.56 ' HB1' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.605 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.704 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.741 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.437 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.443 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.741 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.56 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.605 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.56 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.437 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.438 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.552 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.704 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.491 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.537 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt . . . . . 0 CA--C 1.538 0.494 0 CA-C-O 119.311 -0.376 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.574 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.477 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.677 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.455 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.574 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.735 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.552 ' H ' ' HB3' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.455 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.458 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.458 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.532 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.677 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.735 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.552 ' HB3' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt . . . . . 0 CA--C 1.541 0.616 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.657 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.411 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 8' ' ' CYS . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.407 ' H ' HD21 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASN . . . . . 0.549 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.412 ' H ' ' HB2' ' A' ' 17' ' ' ASN . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.68 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . 0.411 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ILE . . . . . 0.4 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.4 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.633 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.657 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.643 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 18.7 t . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 120.875 0.369 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt -149.89 156.85 38.33 Favored Pre-proline 0 CA--C 1.54 0.596 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.189 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.48 HH12 ' ND2' ' A' ' 17' ' ' ASN . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.606 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.606 HG13 ' O ' ' A' ' 6' ' ' GLY . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.693 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.693 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.48 ' ND2' HH12 ' A' ' 4' ' ' ARG . 0.3 OUTLIER -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.67 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.67 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.603 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.468 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.439 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.439 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.509 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.514 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.603 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.51 0.195 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -125.98 155.92 72.48 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.122 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.534 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.553 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.582 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.548 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.463 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.548 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.2 p-10 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.443 ' H ' HD21 ' A' ' 17' ' ' ASN . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.631 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.463 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.457 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG21 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.562 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.582 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.534 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.349 0.119 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -111.47 135.07 21.05 Favored Pre-proline 0 N--CA 1.474 0.726 0 O-C-N 123.535 0.522 . . . . 0.0 110.246 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.641 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.641 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.468 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.497 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.434 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.434 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.468 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.578 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.7 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.433 ' H ' HD21 ' A' ' 17' ' ' ASN . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.578 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.497 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.502 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.567 ' O ' HD11 ' A' ' 25' ' ' ILE . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.454 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.7 t . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.781 0.324 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -134.69 133.13 21.01 Favored Pre-proline 0 CA--C 1.539 0.54 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.73 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.416 ' HA ' ' ND2' ' A' ' 17' ' ' ASN . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.496 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.582 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.582 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.798 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.417 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.417 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.798 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.508 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 17.9 m-20 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.496 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.508 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.413 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.433 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.433 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.559 HG22 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.486 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.419 ' O ' HD12 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 49.4 t . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.546 0.212 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.788 HD13 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER -127.22 137.35 30.47 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.762 -179.77 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.567 HG22 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.891 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.614 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.626 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.891 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.673 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.451 ' N ' HD21 ' A' ' 17' ' ' ASN . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.673 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.597 HD12 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.483 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.483 HG21 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.788 ' SG ' HD13 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.597 ' OXT' HD12 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.606 0.241 . . . . 0.0 111.301 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.69 HD13 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp -144.14 159.78 51.45 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.78 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.514 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.723 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.556 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.512 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.556 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.536 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.69 ' SG ' HD13 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 2' ' ' ILE . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.488 HD21 ' N ' ' A' ' 18' ' ' SER . 0.6 OUTLIER -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.488 ' N ' HD21 ' A' ' 17' ' ' ASN . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.713 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.512 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.553 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.723 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.713 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.696 0.284 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.556 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt -143.78 117.78 5.99 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.529 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.508 ' HG2' ' O ' ' A' ' 26' ' ' CYS . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.485 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.52 HD11 ' O ' ' A' ' 7' ' ' ILE . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.518 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.412 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.454 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.454 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.42 ' O ' HD23 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.556 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.615 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.408 ' H ' ' HB2' ' A' ' 17' ' ' ASN . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.808 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.412 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.513 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.533 ' O ' HD12 ' A' ' 25' ' ' ILE . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.808 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.423 ' HB1' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.375 0.131 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.443 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER -135.79 151.86 74.9 Favored Pre-proline 0 N--CA 1.467 0.398 0 CA-C-N 116.307 -0.406 . . . . 0.0 112.006 -179.64 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.601 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.415 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.43 ' H ' ' H ' ' A' ' 26' ' ' CYS . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.692 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.4 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.409 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.692 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.557 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.519 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.557 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.564 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.405 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.533 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.409 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.412 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.601 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.564 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.346 0.117 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -118.11 133.56 23.42 Favored Pre-proline 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 178.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.651 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.651 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.608 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.461 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.441 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.441 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.608 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.586 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.492 ' N ' HD21 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.789 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.461 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.572 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.638 ' O ' HD12 ' A' ' 25' ' ' ILE . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.789 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 51.3 t . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.656 0.265 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.488 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.1 pt -143.71 155.71 59.75 Favored Pre-proline 0 CA--C 1.54 0.588 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.31 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.491 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.663 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.755 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.551 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.551 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.47 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.551 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.488 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.434 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.745 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.745 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.551 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.428 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.538 ' C ' HG23 ' A' ' 7' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.755 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.429 ' HB2' ' HE ' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.564 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt -140.71 141.62 25.55 Favored Pre-proline 0 CA--C 1.538 0.496 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.302 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.452 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.452 HD11 ' C ' ' A' ' 6' ' ' GLY . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.478 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.402 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.402 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.564 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.734 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.472 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.734 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.468 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.468 HD13 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.468 ' OXT' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.3 0.095 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -128.37 153.97 79.11 Favored Pre-proline 0 N--CA 1.468 0.473 0 O-C-N 123.348 0.405 . . . . 0.0 112.076 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.448 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.623 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.486 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.429 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.449 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.449 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.41 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.448 ' H ' HD21 ' A' ' 17' ' ' ASN . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.596 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.429 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.589 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.561 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.448 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.608 0.242 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -136.74 155.93 76.36 Favored Pre-proline 0 CA--C 1.538 0.502 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.364 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . . . . . . . . . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.658 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.658 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.473 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.42 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.735 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.735 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.42 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.484 HD13 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG21 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.471 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.634 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.484 ' O ' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.6 0.238 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.4 148.37 65.77 Favored Pre-proline 0 CA--C 1.539 0.55 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.412 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.629 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.629 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.457 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.424 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.424 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.442 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.731 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.457 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.531 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.553 ' O ' HD11 ' A' ' 25' ' ' ILE . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.672 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.721 0.296 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.632 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt -150.21 157.14 37.47 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.045 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.621 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.467 ' C ' HD13 ' A' ' 7' ' ' ILE . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.53 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.41 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.632 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.659 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.659 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.448 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.41 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.563 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.621 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.448 ' HB1' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.662 0.268 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.705 HD11 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -111.27 144.75 31.12 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.336 -179.761 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.441 ' C ' HD11 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 12' ' ' LEU . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.444 ' SG ' ' HA2' ' A' ' 14' ' ' GLY . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.424 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.444 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.705 ' SG ' HD11 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.439 ' H ' HD21 ' A' ' 17' ' ' ASN . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.481 HD13 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.406 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.424 ' H ' ' CG2' ' A' ' 10' ' ' VAL . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.456 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.481 ' OXT' HD13 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 t . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.739 0.304 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.467 HD12 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -163.12 147.29 8.88 Favored Pre-proline 0 N--CA 1.466 0.336 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.13 179.138 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.512 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.63 ' O ' HG21 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.63 HG21 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.666 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.42 ' CD2' ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.42 ' H ' ' CD2' ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.666 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.589 ' ND2' ' H ' ' A' ' 18' ' ' SER . 1.9 p-10 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.589 ' H ' ' ND2' ' A' ' 17' ' ' ASN . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.453 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.56 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.455 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.598 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.512 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.56 ' HB1' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.435 0.159 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -132.42 156.72 79.77 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.792 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.605 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.55 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.704 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.741 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.437 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.443 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.741 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.56 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.605 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.56 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.437 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.438 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.552 ' O ' HG22 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.704 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.503 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.491 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.496 0.188 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.537 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt -115.43 125.56 28.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.403 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.574 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.477 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.677 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.455 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.537 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.612 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.574 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.735 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.552 ' H ' ' HB3' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.455 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.458 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.458 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.532 ' O ' HG21 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.677 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.735 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.552 ' HB3' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.659 0.266 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt -141.44 140.61 20.87 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.795 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.504 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.58 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.657 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.503 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.411 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' VAL . . . . . 0.417 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.432 ' O ' ' O ' ' A' ' 8' ' ' CYS . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.407 ' H ' HD21 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . 0.549 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.412 ' H ' ' HB2' ' A' ' 17' ' ' ASN . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.68 ' O ' ' HB3' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . 0.411 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ILE . . . . . 0.4 HG21 ' H ' ' A' ' 23' ' ' PHE . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.4 ' H ' HG21 ' A' ' 22' ' ' ILE . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.633 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.657 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.643 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 CA--C 1.54 0.596 0 CA-C-O 119.402 -0.332 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.578 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.611 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.629 HD13 ' HB3' ' A' ' 11' ' ' ALA . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.629 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.663 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.425 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.467 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.617 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.617 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.599 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.541 0.612 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.653 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.557 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.647 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.475 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.645 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 2.3 p30 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.645 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.475 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.441 ' H ' HG22 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.57 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.647 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.653 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.474 0.726 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.519 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.724 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.511 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.551 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.514 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.426 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.519 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.539 0.54 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.595 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.688 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.796 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.459 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.459 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.528 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 5.8 m120 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.51 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.569 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.428 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.703 HD12 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.762 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.442 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.673 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.878 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.619 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.635 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.878 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.687 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 4.5 p30 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.454 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.487 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.703 ' SG ' HD12 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.589 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.674 HD11 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp . . . . . 0 CA--C 1.545 0.754 0 CA-C-O 119.175 -0.441 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.796 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.525 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.541 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.674 ' SG ' HD11 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.724 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.525 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.56 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.796 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.724 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.562 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt . . . . . 0 CA--C 1.539 0.534 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.525 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.566 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.566 ' H ' HD23 ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.483 ' O ' HD22 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.562 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.629 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.818 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.424 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.818 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.459 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.467 0.398 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.604 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.414 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.441 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.463 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.684 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.419 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.433 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.574 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.584 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.574 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.516 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.402 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.45 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.422 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.534 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.534 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.604 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' NH1' ' A' ' 4' ' ' ARG . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.701 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.738 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.738 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.606 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.49 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.49 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.5 ' N ' HD22 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.784 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.58 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.58 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.655 HD11 HD22 ' A' ' 12' ' ' LEU . 1.1 pt . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 119.507 -0.283 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.561 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.828 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.563 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.463 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.655 HD22 HD11 ' A' ' 2' ' ' ILE . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.478 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.758 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.758 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.563 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.417 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.417 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.828 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt . . . . . 0 CA--C 1.538 0.496 0 CA-C-O 119.6 -0.238 . . . . 0.0 111.302 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.466 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.411 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.415 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.415 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.577 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.75 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.55 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.75 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.465 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.46 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.696 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.46 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.689 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.516 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.516 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.487 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.613 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.6 p30 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.613 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.46 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.414 HD11 HD13 ' A' ' 12' ' ' LEU . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.502 0 CA-C-O 119.425 -0.322 . . . . 0.0 110.364 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.429 ' HD2' ' H ' ' A' ' 18' ' ' SER . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.476 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 2' ' ' ILE . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.556 ' H ' ' CG ' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.747 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.429 ' H ' ' HD2' ' A' ' 4' ' ' ARG . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.747 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.434 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.49 HD11 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.642 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.539 0.55 0 CA-C-O 119.145 -0.455 . . . . 0.0 110.412 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.539 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.674 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.471 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.416 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.416 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.452 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.403 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.471 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.542 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.542 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.676 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.628 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt . . . . . 0 CA--C 1.542 0.644 0 CA-C-O 119.433 -0.318 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.624 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.547 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.488 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.627 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.628 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.677 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.421 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.627 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.71 HD12 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 119.13 -0.462 . . . . 0.0 110.336 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.607 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.442 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.509 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HA ' ' CB ' ' A' ' 12' ' ' LEU . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.441 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.435 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' HD12 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.617 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 2.0 p30 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.443 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.432 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.539 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.54 HG22 ' HA2' ' A' ' 5' ' ' GLY . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.607 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.476 HD11 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 119.679 -0.2 . . . . 0.0 111.13 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.657 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.658 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.485 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.487 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.658 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.4 p30 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.474 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.485 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HD13 ' A' ' 25' ' ' ILE . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 22' ' ' ILE . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.537 ' O ' HD11 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.773 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.73 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ALA . . . . . 0.669 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.73 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.576 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.615 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.576 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.45 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.437 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.437 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.773 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.494 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.526 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt . . . . . 0 CA--C 1.538 0.494 0 CA-C-O 119.311 -0.376 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.583 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.498 ' H ' ' HB3' ' A' ' 26' ' ' CYS . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.747 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.406 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.467 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.526 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.583 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.762 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.503 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.467 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.588 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.747 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.762 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.523 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt . . . . . 0 CA--C 1.541 0.616 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ARG . . . . . 0.516 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.74 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.506 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' HA2' ' A' ' 24' ' ' GLY . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.483 ' H ' HD23 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASN . . . . . 0.563 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 9.5 p30 -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.681 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.693 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.74 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.653 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 18.7 t . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 120.875 0.369 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt -149.89 156.85 38.33 Favored Pre-proline 0 CA--C 1.54 0.596 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.189 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.578 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.611 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.629 HD13 ' HB3' ' A' ' 11' ' ' ALA . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.629 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 11.4 p30 -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.663 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.425 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.467 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.617 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.617 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.599 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.51 0.195 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -125.98 155.92 72.48 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.122 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.653 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.557 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.647 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.475 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.645 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 2.3 p30 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.645 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.475 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.441 ' H ' HG22 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.57 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.647 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.653 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.349 0.119 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -111.47 135.07 21.05 Favored Pre-proline 0 N--CA 1.474 0.726 0 O-C-N 123.535 0.522 . . . . 0.0 110.246 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.519 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.724 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.511 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.551 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.514 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.426 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.519 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.7 t . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.781 0.324 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -134.69 133.13 21.01 Favored Pre-proline 0 CA--C 1.539 0.54 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.73 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.595 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.688 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.796 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.459 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.459 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.528 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 5.8 m120 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.51 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.569 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.428 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 49.4 t . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.546 0.212 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.703 HD12 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER -127.22 137.35 30.47 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.762 -179.77 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.442 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.673 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.878 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.619 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.635 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.878 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.687 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 4.5 p30 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.454 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.487 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.703 ' SG ' HD12 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.589 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.606 0.241 . . . . 0.0 111.301 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.674 HD11 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp -144.14 159.78 51.45 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.78 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.796 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.525 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.541 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.674 ' SG ' HD11 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.429 ' HB2' ' H ' ' A' ' 2' ' ' ILE . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.2 p30 -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.724 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.525 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.56 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.796 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.724 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.696 0.284 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt -143.78 117.78 5.99 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.525 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.566 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.566 ' H ' HD23 ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' O ' HD22 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.562 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.629 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.818 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.424 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.818 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.375 0.131 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.459 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER -135.79 151.86 74.9 Favored Pre-proline 0 N--CA 1.467 0.398 0 CA-C-N 116.307 -0.406 . . . . 0.0 112.006 -179.64 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.604 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.414 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.441 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.463 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.684 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.419 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.433 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.574 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.584 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.574 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.516 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.402 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.45 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.422 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.534 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.534 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.604 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.346 0.117 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -118.11 133.56 23.42 Favored Pre-proline 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 178.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' NH1' ' A' ' 4' ' ' ARG . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.701 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.738 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.738 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.606 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.49 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.49 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.5 ' N ' HD22 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.784 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.58 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.58 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 51.3 t . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.656 0.265 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.655 HD11 HD22 ' A' ' 12' ' ' LEU . 1.1 pt -143.71 155.71 59.75 Favored Pre-proline 0 CA--C 1.54 0.588 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.31 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.561 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.828 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.563 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.463 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.655 HD22 HD11 ' A' ' 2' ' ' ILE . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.478 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.758 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.758 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.563 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.417 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.417 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.828 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt -140.71 141.62 25.55 Favored Pre-proline 0 CA--C 1.538 0.496 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.302 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.466 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.411 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.415 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.415 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.577 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.75 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.55 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.75 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.465 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.46 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.696 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.3 0.095 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -128.37 153.97 79.11 Favored Pre-proline 0 N--CA 1.468 0.473 0 O-C-N 123.348 0.405 . . . . 0.0 112.076 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.46 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.689 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.516 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.516 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.487 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.613 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.6 p30 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.613 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.46 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.608 0.242 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.414 HD11 HD13 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -136.74 155.93 76.36 Favored Pre-proline 0 CA--C 1.538 0.502 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.364 179.504 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.429 ' HD2' ' H ' ' A' ' 18' ' ' SER . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.476 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 2' ' ' ILE . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.556 ' H ' ' CG ' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.747 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.429 ' H ' ' HD2' ' A' ' 4' ' ' ARG . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.747 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.434 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.49 HD11 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.642 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.6 0.238 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.4 148.37 65.77 Favored Pre-proline 0 CA--C 1.539 0.55 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.412 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.539 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.674 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.471 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.416 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.416 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.452 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.403 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.471 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.542 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.542 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.676 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.721 0.296 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.628 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt -150.21 157.14 37.47 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.045 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.624 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.547 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.488 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.627 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.628 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.677 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.421 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.627 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.662 0.268 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.71 HD12 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -111.27 144.75 31.12 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.336 -179.761 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.607 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.442 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.509 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HA ' ' CB ' ' A' ' 12' ' ' LEU . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.441 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.435 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' HD12 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.617 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 2.0 p30 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.443 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.432 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.539 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.54 HG22 ' HA2' ' A' ' 5' ' ' GLY . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.607 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 t . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.739 0.304 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.476 HD11 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -163.12 147.29 8.88 Favored Pre-proline 0 N--CA 1.466 0.336 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.13 179.138 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.657 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.658 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.485 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.487 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.658 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.4 p30 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.474 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.485 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HD13 ' A' ' 25' ' ' ILE . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 22' ' ' ILE . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.537 ' O ' HD11 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.435 0.159 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -132.42 156.72 79.77 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.792 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.773 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.73 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.669 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.73 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.576 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.615 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.576 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.45 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.437 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.437 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.773 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.494 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.496 0.188 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.526 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt -115.43 125.56 28.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.403 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.583 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.498 ' H ' ' HB3' ' A' ' 26' ' ' CYS . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.747 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.406 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.467 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.526 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.583 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.762 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.503 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.467 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.588 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.747 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.762 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.523 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.659 0.266 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt -141.44 140.61 20.87 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.795 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.516 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.74 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.506 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' HA2' ' A' ' 24' ' ' GLY . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.483 ' H ' HD23 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASN . . . . . 0.563 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 9.5 p30 -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.681 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.693 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.74 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.653 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt . . . . . 0 CA--C 1.54 0.596 0 CA-C-O 119.402 -0.332 . . . . 0.0 111.189 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.578 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.611 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.629 HD13 ' HB3' ' A' ' 11' ' ' ALA . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.629 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.494 ' ND2' HH12 ' A' ' 4' ' ' ARG . 0.3 OUTLIER -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.663 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.425 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.467 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.617 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.617 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.599 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.541 0.612 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.653 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.557 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.647 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.475 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.645 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.2 p-10 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.478 ' H ' HD22 ' A' ' 17' ' ' ASN . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.645 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.475 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.441 ' H ' HG22 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.57 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.647 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.653 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.474 0.726 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.519 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.724 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.511 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.551 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.7 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.474 ' H ' HD22 ' A' ' 17' ' ' ASN . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.514 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.426 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.519 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.539 0.54 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.408 ' HA ' ' ND2' ' A' ' 17' ' ' ASN . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.595 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.688 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.796 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.459 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.459 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.528 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 17.9 m-20 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.51 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.569 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.428 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.703 HD12 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER . . . . . 0 CA--C 1.537 0.461 0 CA-C-O 119.487 -0.292 . . . . 0.0 111.762 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.442 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.673 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.878 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.619 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.635 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.878 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.687 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.467 ' H ' HD22 ' A' ' 17' ' ' ASN . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.454 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.487 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.703 ' SG ' HD12 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.589 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.674 HD11 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp . . . . . 0 CA--C 1.545 0.754 0 CA-C-O 119.175 -0.441 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.796 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.525 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.541 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.674 ' SG ' HD11 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.504 HD22 ' N ' ' A' ' 18' ' ' SER . 0.6 OUTLIER -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.504 ' N ' HD22 ' A' ' 17' ' ' ASN . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.724 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.525 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.56 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.796 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.724 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.562 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt . . . . . 0 CA--C 1.539 0.534 0 CA-C-O 119.622 -0.228 . . . . 0.0 111.16 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.525 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.566 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.566 ' H ' HD23 ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.483 ' O ' HD22 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.562 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.629 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.818 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.424 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.818 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.459 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER . . . . . 0 N--CA 1.467 0.398 0 N-CA-C 112.006 0.372 . . . . 0.0 112.006 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.604 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.414 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.441 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.463 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.684 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.419 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.433 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.574 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.584 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.574 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.516 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.402 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.45 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.422 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.534 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.534 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.604 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' NH1' ' A' ' 4' ' ' ARG . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.701 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.738 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.738 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.606 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.49 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.49 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.5 ' N ' HD22 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.784 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.58 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.58 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.655 HD11 HD22 ' A' ' 12' ' ' LEU . 1.1 pt . . . . . 0 CA--C 1.54 0.588 0 CA-C-O 119.507 -0.283 . . . . 0.0 111.31 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.561 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.828 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.563 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.463 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.655 HD22 HD11 ' A' ' 2' ' ' ILE . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.478 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.758 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.758 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.563 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.417 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.417 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.828 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt . . . . . 0 CA--C 1.538 0.496 0 CA-C-O 119.6 -0.238 . . . . 0.0 111.302 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.466 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.411 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.415 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.415 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.577 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.75 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.55 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.75 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.465 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.46 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.696 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 112.076 0.398 . . . . 0.0 112.076 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.46 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.689 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.516 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.516 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.487 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.613 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.496 ' H ' HD22 ' A' ' 17' ' ' ASN . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.613 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.46 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.414 HD11 HD13 ' A' ' 12' ' ' LEU . 0.4 OUTLIER . . . . . 0 CA--C 1.538 0.502 0 CA-C-O 119.425 -0.322 . . . . 0.0 110.364 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.429 ' HD2' ' H ' ' A' ' 18' ' ' SER . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.476 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.434 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 2' ' ' ILE . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.556 ' H ' ' CG ' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.747 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.429 ' H ' ' HD2' ' A' ' 4' ' ' ARG . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.747 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.434 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.49 HD11 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.642 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.539 0.55 0 CA-C-O 119.145 -0.455 . . . . 0.0 110.412 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.539 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.674 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.471 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.416 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.416 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.452 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.403 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.471 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.542 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.542 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.676 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.628 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt . . . . . 0 CA--C 1.542 0.644 0 CA-C-O 119.433 -0.318 . . . . 0.0 111.045 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.624 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.547 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.488 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.627 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.628 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.677 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.421 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.627 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.71 HD12 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER . . . . . 0 CA--C 1.538 0.513 0 CA-C-O 119.13 -0.462 . . . . 0.0 110.336 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.607 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.442 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.509 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HA ' ' CB ' ' A' ' 12' ' ' LEU . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.441 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.435 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' HD12 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.617 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.474 ' H ' HD22 ' A' ' 17' ' ' ASN . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.443 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.432 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.539 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.54 HG22 ' HA2' ' A' ' 5' ' ' GLY . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.607 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.476 HD11 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.466 0.336 0 CA-C-O 119.679 -0.2 . . . . 0.0 111.13 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.657 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.658 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.485 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.487 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.658 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.618 ' ND2' ' H ' ' A' ' 18' ' ' SER . 1.9 p-10 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.618 ' H ' ' ND2' ' A' ' 17' ' ' ASN . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.474 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.485 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HD13 ' A' ' 25' ' ' ILE . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 22' ' ' ILE . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.537 ' O ' HD11 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 CA--C 1.537 0.473 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.773 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.73 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . 0.669 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.73 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.576 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.615 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.576 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.45 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.437 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.437 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.773 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.494 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.526 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt . . . . . 0 CA--C 1.538 0.494 0 CA-C-O 119.311 -0.376 . . . . 0.0 110.403 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.583 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.498 ' H ' ' HB3' ' A' ' 26' ' ' CYS . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.747 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.406 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.467 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.526 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.583 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.762 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.503 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.467 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.588 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.747 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.762 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.523 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt . . . . . 0 CA--C 1.541 0.616 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ARG . . . . . 0.516 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.74 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.506 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' HA2' ' A' ' 24' ' ' GLY . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.483 ' H ' HD23 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASN . . . . . 0.563 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.681 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.693 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.74 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.653 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 18.7 t . . . . . 0 N--CA 1.484 1.251 0 CA-C-O 120.875 0.369 . . . . 0.0 110.888 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.2 pt -149.89 156.85 38.33 Favored Pre-proline 0 CA--C 1.54 0.596 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.189 179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -81.19 174.04 11.15 Favored 'Trans proline' 0 C--N 1.374 1.882 0 C-N-CA 122.594 2.196 . . . . 0.0 113.648 -179.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.578 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -62.2 124.03 19.76 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 124.303 1.041 . . . . 0.0 111.663 179.347 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 98.98 33.37 5.53 Favored Glycine 0 N--CA 1.451 -0.312 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.087 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.611 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.14 40.12 1.72 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 121.086 -0.578 . . . . 0.0 113.962 -179.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.629 HD13 ' HB3' ' A' ' 11' ' ' ALA . 2.1 pp 45.4 120.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 C-N-CA 125.07 1.348 . . . . 0.0 113.958 178.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.685 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 17.0 t -141.01 -7.78 1.05 Allowed 'General case' 0 CA--C 1.544 0.724 0 N-CA-C 112.756 0.651 . . . . 0.0 112.756 -179.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -121.35 -20.28 6.72 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 117.863 0.301 . . . . 0.0 111.593 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.3 p -86.78 -32.3 6.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.056 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.629 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -134.86 -43.8 0.73 Allowed 'General case' 0 N--CA 1.469 0.476 0 O-C-N 123.41 0.444 . . . . 0.0 111.888 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.21 -179.6 5.92 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.251 -179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.8 m -126.05 -19.75 4.71 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.444 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.71 158.53 30.4 Favored Glycine 0 C--N 1.34 0.757 0 O-C-N 123.446 0.467 . . . . 0.0 112.971 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.685 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 90.0 m -123.28 -149.31 0.42 Allowed 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 122.534 0.334 . . . . 0.0 110.827 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -88.26 -64.94 1.07 Allowed 'General case' 0 C--N 1.349 0.544 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.494 ' ND2' HH12 ' A' ' 4' ' ' ARG . 0.3 OUTLIER -144.99 135.51 24.33 Favored 'General case' 0 N--CA 1.482 1.138 0 N-CA-C 113.938 1.088 . . . . 0.0 113.938 -178.329 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.663 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 52.4 m 57.18 46.22 1.97 Allowed Pre-proline 0 N--CA 1.481 1.08 0 C-N-CA 124.949 1.299 . . . . 0.0 111.354 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.663 ' HD3' ' N ' ' A' ' 18' ' ' SER . 69.2 Cg_endo -100.35 99.19 0.05 OUTLIER 'Trans proline' 0 N--CA 1.438 -1.791 0 C-N-CA 121.554 1.503 . . . . 0.0 114.946 -178.311 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.425 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -65.98 -26.07 72.21 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 115.773 -0.648 . . . . 0.0 113.197 178.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.467 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.8 m 57.84 108.08 0.01 OUTLIER 'General case' 0 C--N 1.359 1.002 0 C-N-CA 123.674 0.789 . . . . 0.0 112.079 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.438 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.7 OUTLIER -123.81 -167.95 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.337 179.379 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.438 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.8 t80 -85.0 98.64 10.51 Favored 'General case' 0 CA--C 1.539 0.547 0 N-CA-C 112.53 0.566 . . . . 0.0 112.53 -178.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.617 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 99.93 13.26 37.56 Favored Glycine 0 C--N 1.342 0.905 0 CA-C-O 118.595 -1.114 . . . . 0.0 115.518 177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.617 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -175.67 139.72 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 CA-C-N 118.577 1.189 . . . . 0.0 110.339 -179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 52.8 t -82.16 105.91 13.62 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-O 120.91 0.386 . . . . 0.0 110.272 177.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.599 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.485 1.318 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.749 -179.037 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 25.0 t . . . . . 0 N--CA 1.487 1.38 0 CA-C-O 120.51 0.195 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -125.98 155.92 72.48 Favored Pre-proline 0 CA--C 1.541 0.612 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.122 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -84.33 -147.35 0.03 OUTLIER 'Trans proline' 0 C--N 1.375 1.955 0 C-N-CA 123.027 2.485 . . . . 0.0 112.684 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.653 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -95.05 124.06 38.89 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.102 0.561 . . . . 0.0 110.575 -179.914 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.88 30.41 4.55 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.371 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.557 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.3 47.51 1.02 Allowed Glycine 0 C--N 1.341 0.843 0 C-N-CA 121.082 -0.58 . . . . 0.0 114.043 -179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.647 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.9 pp 42.36 119.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 C-N-CA 125.107 1.363 . . . . 0.0 114.281 178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.54 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 13.2 t -141.8 -17.15 0.77 Allowed 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 113.356 0.873 . . . . 0.0 113.356 -179.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.475 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -110.38 -9.31 14.62 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 117.888 0.313 . . . . 0.0 110.979 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.3 p -99.53 -26.85 3.63 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.029 -178.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.3 -45.82 0.29 Allowed 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -84.97 -170.61 3.21 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.465 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.9 m -127.78 -29.16 2.63 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.32 160.39 33.73 Favored Glycine 0 C--N 1.335 0.523 0 C-N-CA 120.906 -0.664 . . . . 0.0 113.62 -179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.54 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 6.7 m -134.54 -158.68 0.9 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 122.85 0.46 . . . . 0.0 110.41 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.4 m -80.41 165.53 22.14 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 122.761 0.425 . . . . 0.0 111.596 179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.645 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.2 p-10 44.09 -126.99 0.95 Allowed 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 124.532 1.133 . . . . 0.0 112.751 179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.478 ' H ' HD22 ' A' ' 17' ' ' ASN . 21.1 t -106.69 82.88 1.11 Allowed Pre-proline 0 C--O 1.238 0.5 0 C-N-CA 122.614 0.366 . . . . 0.0 110.681 179.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.645 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 43.3 Cg_endo -94.39 97.98 0.12 Allowed 'Trans proline' 0 C--N 1.365 1.435 0 C-N-CA 122.756 2.304 . . . . 0.0 112.868 179.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -57.8 -27.08 58.72 Favored Glycine 0 CA--C 1.53 0.979 0 CA-C-N 114.923 -1.035 . . . . 0.0 114.375 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.475 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.7 m 60.41 112.58 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.142 0 C-N-CA 123.411 0.685 . . . . 0.0 111.839 179.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.441 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -125.38 -176.8 1.46 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.29 179.132 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.441 ' H ' HG22 ' A' ' 22' ' ' ILE . 8.9 t80 -78.73 98.06 6.11 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.57 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 104.13 8.37 38.99 Favored Glycine 0 C--N 1.342 0.879 0 N-CA-C 115.771 1.069 . . . . 0.0 115.771 177.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.647 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -174.23 140.95 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.051 0 CA-C-N 118.555 1.177 . . . . 0.0 110.199 -179.202 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 43.0 t -83.47 80.13 9.2 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-O 121.311 0.577 . . . . 0.0 110.055 177.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.653 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.26 0 C-N-CA 123.965 0.906 . . . . 0.0 111.806 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.485 1.316 0 CA-C-O 120.349 0.119 . . . . 0.0 111.211 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -111.47 135.07 21.05 Favored Pre-proline 0 N--CA 1.474 0.726 0 O-C-N 123.535 0.522 . . . . 0.0 110.246 179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -66.44 168.78 15.46 Favored 'Trans proline' 0 C--N 1.375 1.967 0 C-N-CA 122.606 2.204 . . . . 0.0 113.44 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.519 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 11.1 mtp180 -93.31 128.51 39.36 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.668 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.05 19.71 5.48 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 114.636 -1.165 . . . . 0.0 110.219 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.98 -78.54 1.01 Allowed Glycine 0 C--N 1.34 0.767 0 CA-C-N 114.939 -0.63 . . . . 0.0 112.695 -179.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.724 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 179.11 139.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 C-N-CA 123.982 0.913 . . . . 0.0 109.93 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.463 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.0 t -154.49 -61.52 0.13 Allowed 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.511 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.2 tp -69.84 -4.38 19.93 Favored 'General case' 0 N--CA 1.485 1.284 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -179.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 11.3 p -94.12 -34.86 5.88 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.952 -178.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.62 -39.56 0.42 Allowed 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.551 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -85.37 -169.22 2.55 Favored 'General case' 0 CA--C 1.543 0.705 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.501 -179.024 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.551 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -124.11 -29.82 3.55 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.406 0.282 . . . . 0.0 111.516 179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -176.83 144.7 6.98 Favored Glycine 0 C--N 1.334 0.444 0 CA-C-N 115.873 -0.603 . . . . 0.0 112.388 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.463 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.6 m -106.35 -152.4 0.47 Allowed 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.584 0.226 . . . . 0.0 110.761 -179.838 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.7 t -83.39 161.77 21.25 Favored 'General case' 0 C--N 1.346 0.419 0 C-N-CA 122.656 0.382 . . . . 0.0 111.634 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.597 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.7 OUTLIER 45.31 -113.71 0.4 Allowed 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 124.714 1.205 . . . . 0.0 113.633 179.718 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.474 ' H ' HD22 ' A' ' 17' ' ' ASN . 52.8 m -109.14 83.09 2.15 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 122.469 0.308 . . . . 0.0 111.527 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.597 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 34.0 Cg_endo -95.8 95.42 0.1 OUTLIER 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 122.941 2.427 . . . . 0.0 112.915 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -58.24 -30.55 64.46 Favored Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.686 -0.688 . . . . 0.0 113.274 179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.511 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 34.7 m 58.96 114.68 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.936 0.894 . . . . 0.0 112.51 179.052 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.15 166.93 26.49 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 114.499 -1.228 . . . . 0.0 108.938 179.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -70.42 89.6 0.69 Allowed 'General case' 0 CA--C 1.542 0.645 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -178.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.514 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.29 -11.38 7.64 Favored Glycine 0 C--N 1.342 0.915 0 CA-C-O 118.703 -1.054 . . . . 0.0 115.402 178.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.539 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.4 pp -167.04 141.97 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 CA-C-N 118.562 1.181 . . . . 0.0 110.399 -178.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.426 ' H ' ' N ' ' A' ' 7' ' ' ILE . 38.9 t -75.26 94.04 2.94 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-O 121.033 0.444 . . . . 0.0 110.164 177.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.519 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.486 1.329 0 C-N-CA 124.044 0.938 . . . . 0.0 111.713 -178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.7 t . . . . . 0 N--CA 1.484 1.262 0 CA-C-O 120.781 0.324 . . . . 0.0 110.86 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -134.69 133.13 21.01 Favored Pre-proline 0 CA--C 1.539 0.54 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.73 179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.408 ' HA ' ' ND2' ' A' ' 17' ' ' ASN . 26.7 Cg_exo -63.82 -171.36 0.14 Allowed 'Trans proline' 0 C--N 1.376 2.012 0 C-N-CA 122.526 2.151 . . . . 0.0 113.386 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.595 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -82.78 135.45 34.97 Favored 'General case' 0 N--CA 1.468 0.427 0 C-N-CA 123.37 0.668 . . . . 0.0 110.307 -179.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 99.43 32.94 5.56 Favored Glycine 0 N--CA 1.451 -0.314 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.688 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -114.1 -89.79 1.73 Allowed Glycine 0 C--N 1.339 0.739 0 O-C-N 124.081 0.518 . . . . 0.0 112.576 -179.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 178.64 136.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 C-N-CA 124.167 0.987 . . . . 0.0 109.515 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.796 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.4 t -152.04 -64.53 0.17 Allowed 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.4 tp -69.61 1.3 4.27 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.8 p -99.98 -36.55 5.25 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.659 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.607 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.81 -37.92 0.4 Allowed 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 -179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.459 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -87.09 -165.99 1.45 Allowed 'General case' 0 CA--C 1.541 0.613 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.625 -178.844 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.459 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.0 t -131.85 -19.59 2.6 Favored 'General case' 0 C--O 1.236 0.351 0 C-N-CA 122.77 0.428 . . . . 0.0 110.967 179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -179.4 124.95 0.93 Allowed Glycine 0 C--N 1.34 0.754 0 O-C-N 123.514 0.509 . . . . 0.0 112.53 179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.796 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 12.2 m -95.31 -163.79 1.09 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.44 0.296 . . . . 0.0 110.323 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.64 168.57 12.9 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 122.252 0.221 . . . . 0.0 111.095 179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.528 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 17.9 m-20 66.07 -130.41 0.22 Allowed 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 123.609 0.764 . . . . 0.0 110.361 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.51 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -111.34 80.11 2.44 Favored Pre-proline 0 C--O 1.238 0.489 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.528 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 89.5 Cg_endo -90.71 96.4 0.25 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 122.547 2.165 . . . . 0.0 114.184 -178.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.569 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.99 -19.32 65.6 Favored Glycine 0 CA--C 1.529 0.915 0 CA-C-N 114.938 -1.028 . . . . 0.0 112.439 177.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 39.7 m 60.17 114.09 0.01 OUTLIER 'General case' 0 C--N 1.355 0.812 0 C-N-CA 124.556 1.142 . . . . 0.0 113.159 178.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.428 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.6 OUTLIER -130.84 -179.12 3.03 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 CA-C-N 114.594 -1.184 . . . . 0.0 108.732 178.482 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.0 t80 -78.76 87.59 4.65 Favored 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 119.18 -5.41 13.45 Favored Glycine 0 C--N 1.343 0.966 0 N-CA-C 116.061 1.184 . . . . 0.0 116.061 177.578 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -168.12 144.05 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 CA-C-N 118.894 1.347 . . . . 0.0 111.407 -178.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.491 ' O ' ' HG3' ' A' ' 4' ' ' ARG . 2.5 m -76.55 99.86 5.11 Favored 'General case' 0 C--N 1.354 0.781 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.487 1.403 0 CA-C-O 118.198 -0.906 . . . . 0.0 112.145 -179.222 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 49.4 t . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 120.546 0.212 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.703 HD12 ' SG ' ' A' ' 26' ' ' CYS . 0.3 OUTLIER -127.22 137.35 30.47 Favored Pre-proline 0 CA--C 1.537 0.461 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.762 -179.77 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -76.96 -142.56 0.02 OUTLIER 'Trans proline' 0 C--N 1.375 1.939 0 C-N-CA 122.856 2.37 . . . . 0.0 112.165 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.589 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -89.67 128.12 36.03 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 122.88 0.472 . . . . 0.0 110.497 179.828 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.442 ' C ' HG22 ' A' ' 25' ' ' ILE . . . 101.81 39.28 2.96 Favored Glycine 0 N--CA 1.453 -0.207 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.333 -178.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.673 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -119.94 -95.49 1.55 Allowed Glycine 0 C--N 1.338 0.64 0 O-C-N 124.034 0.49 . . . . 0.0 112.511 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.673 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 179.42 134.04 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 C-N-CA 124.385 1.074 . . . . 0.0 108.951 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.878 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 47.0 t -149.56 -61.95 0.22 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 113.544 0.942 . . . . 0.0 113.544 -179.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.454 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.2 tp -68.76 -3.71 13.29 Favored 'General case' 0 N--CA 1.483 1.18 0 CA-C-O 120.843 0.354 . . . . 0.0 111.904 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.2 p -95.77 -44.04 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.631 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.154 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.22 -41.98 0.13 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 113.348 0.87 . . . . 0.0 113.348 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.619 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 2.4 tt -98.13 73.77 2.22 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.635 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 56.8 p -71.19 84.37 0.75 Allowed 'General case' 0 CA--C 1.542 0.64 0 CA-C-O 121.282 0.563 . . . . 0.0 111.177 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 143.2 83.95 0.07 OUTLIER Glycine 0 C--N 1.34 0.753 0 CA-C-N 115.285 -0.87 . . . . 0.0 112.661 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.878 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 15.8 m -104.5 -169.41 1.62 Allowed 'General case' 0 CA--C 1.542 0.647 0 C-N-CA 122.355 0.262 . . . . 0.0 110.409 179.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.1 m -77.0 164.94 25.29 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.687 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 44.94 -131.13 0.94 Allowed 'General case' 0 N--CA 1.492 1.652 0 C-N-CA 124.498 1.119 . . . . 0.0 112.522 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.467 ' H ' HD22 ' A' ' 17' ' ' ASN . 22.2 t -105.3 83.07 0.83 Allowed Pre-proline 0 C--O 1.239 0.52 0 C-N-CA 122.649 0.379 . . . . 0.0 110.225 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.687 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 46.7 Cg_endo -93.77 99.11 0.14 Allowed 'Trans proline' 0 C--N 1.367 1.501 0 C-N-CA 122.512 2.141 . . . . 0.0 113.143 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -52.92 -23.04 13.87 Favored Glycine 0 N--CA 1.473 1.131 0 CA-C-N 115.092 -0.958 . . . . 0.0 113.781 178.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.454 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 54.2 m 61.77 117.36 0.02 OUTLIER 'General case' 0 C--N 1.355 0.829 0 C-N-CA 124.262 1.025 . . . . 0.0 113.201 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.487 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.4 OUTLIER -133.29 170.65 19.53 Favored 'Isoleucine or valine' 0 C--O 1.237 0.407 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.918 178.602 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.2 t80 -71.81 85.31 0.94 Allowed 'General case' 0 CA--C 1.543 0.679 0 N-CA-C 112.182 0.438 . . . . 0.0 112.182 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.489 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.0 -11.27 6.93 Favored Glycine 0 C--N 1.344 1.019 0 N-CA-C 115.805 1.082 . . . . 0.0 115.805 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.489 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -166.56 143.66 1.26 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 CA-C-N 118.679 1.24 . . . . 0.0 111.55 -178.212 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.703 ' SG ' HD12 ' A' ' 2' ' ' ILE . 13.3 m -75.6 110.13 9.75 Favored 'General case' 0 C--N 1.355 0.812 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 177.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.589 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.324 0 C-N-CA 123.692 0.797 . . . . 0.0 112.434 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.484 1.269 0 CA-C-O 120.606 0.241 . . . . 0.0 111.301 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.674 HD11 ' SG ' ' A' ' 15' ' ' CYS . 2.3 pp -144.14 159.78 51.45 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.78 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -82.13 -177.58 3.59 Favored 'Trans proline' 0 C--N 1.374 1.92 0 C-N-CA 122.819 2.346 . . . . 0.0 113.853 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.417 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.3 tpp180 -77.94 111.54 13.9 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 124.221 1.009 . . . . 0.0 110.769 179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.02 35.49 2.16 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.452 -0.794 . . . . 0.0 112.235 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.53 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.46 53.61 0.8 Allowed Glycine 0 C--N 1.341 0.832 0 C-N-CA 120.897 -0.668 . . . . 0.0 114.164 -179.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.796 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 1.1 pt 39.85 120.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 124.977 1.311 . . . . 0.0 114.262 178.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.57 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 44.5 t -140.21 -59.99 0.53 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 113.345 0.868 . . . . 0.0 113.345 -179.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.525 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.4 tp -71.24 -5.26 30.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-O 120.829 0.347 . . . . 0.0 111.91 -179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 4.9 p -91.76 -45.63 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.302 -179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.2 -41.79 0.13 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 112.942 0.719 . . . . 0.0 112.942 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.57 ' O ' ' HA ' ' A' ' 8' ' ' CYS . 1.3 tt -94.76 66.53 3.15 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.943 -178.165 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.541 ' HA ' ' SG ' ' A' ' 8' ' ' CYS . 52.0 p -74.26 99.25 3.39 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 121.268 0.556 . . . . 0.0 110.953 179.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.51 81.42 0.04 OUTLIER Glycine 0 C--N 1.334 0.449 0 CA-C-N 115.001 -1.0 . . . . 0.0 111.684 -179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.674 ' SG ' HD11 ' A' ' 2' ' ' ILE . 92.2 m -86.12 176.83 7.78 Favored 'General case' 0 CA--C 1.535 0.38 0 C-N-CA 122.65 0.38 . . . . 0.0 111.855 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.429 ' HB2' ' H ' ' A' ' 2' ' ' ILE . 10.2 t -71.93 -44.22 64.01 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 -178.782 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.504 HD22 ' N ' ' A' ' 18' ' ' SER . 0.6 OUTLIER -113.2 -127.43 0.29 Allowed 'General case' 0 CA--C 1.545 0.774 0 O-C-N 123.423 0.452 . . . . 0.0 111.974 -178.653 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.504 ' N ' HD22 ' A' ' 17' ' ' ASN . 52.8 m -131.66 69.74 81.34 Favored Pre-proline 0 C--O 1.237 0.446 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.724 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 2.6 Cg_endo -84.65 -31.91 0.4 Allowed 'Trans proline' 0 C--N 1.361 1.189 0 C-N-CA 123.383 2.722 . . . . 0.0 114.184 -177.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.62 -37.33 3.33 Favored Glycine 0 C--N 1.34 0.79 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.829 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.525 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 77.8 m 63.23 115.2 0.02 OUTLIER 'General case' 0 C--N 1.36 1.058 0 CA-C-N 117.481 0.641 . . . . 0.0 111.471 -179.387 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.84 167.81 18.4 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.226 179.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -68.64 88.9 0.36 Allowed 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.56 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 118.56 0.39 15.78 Favored Glycine 0 C--N 1.343 0.919 0 N-CA-C 115.874 1.11 . . . . 0.0 115.874 177.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.796 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -173.45 140.62 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 CA-C-N 118.774 1.287 . . . . 0.0 110.701 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.724 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 38.4 t -76.12 82.12 2.95 Favored 'General case' 0 CA--C 1.545 0.764 0 CA-C-O 121.358 0.599 . . . . 0.0 109.674 177.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.348 0 C-N-CA 124.3 1.04 . . . . 0.0 111.626 -178.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.696 0.284 . . . . 0.0 111.05 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.562 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 pt -143.78 117.78 5.99 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.501 ' HA ' ' OD1' ' A' ' 17' ' ' ASN . 52.9 Cg_exo -57.12 -83.72 0.01 OUTLIER 'Trans proline' 0 C--N 1.373 1.858 0 C-N-CA 122.959 2.439 . . . . 0.0 114.863 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.525 ' HG2' ' HB3' ' A' ' 27' ' ' ALA . 3.4 tmm_? -145.77 123.3 11.74 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 123.285 0.634 . . . . 0.0 110.444 -178.125 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 118.1 18.76 4.96 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 120.903 -0.665 . . . . 0.0 113.349 178.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.623 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.75 -100.42 2.61 Favored Glycine 0 C--N 1.335 0.483 0 C-N-CA 120.86 -0.686 . . . . 0.0 113.658 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.623 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp -176.69 139.84 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 C-N-CA 124.101 0.961 . . . . 0.0 108.991 -177.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.515 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 43.3 t -152.69 -64.51 0.16 Allowed 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 112.518 0.562 . . . . 0.0 112.518 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -67.82 -1.23 5.11 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.017 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 5.0 p -100.09 -31.02 3.33 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.773 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.94 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.57 -43.69 0.36 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.566 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -86.4 -167.77 1.99 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.485 -178.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.566 ' H ' HD23 ' A' ' 12' ' ' LEU . 54.7 m -128.35 -34.52 2.05 Favored 'General case' 0 C--O 1.235 0.328 0 C-N-CA 122.756 0.423 . . . . 0.0 110.561 179.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.483 ' O ' HD22 ' A' ' 12' ' ' LEU . . . -152.34 146.14 14.46 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.214 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.562 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 68.8 m -99.54 -158.1 0.65 Allowed 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 122.408 0.283 . . . . 0.0 111.005 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 t -72.77 -44.79 61.14 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.954 0.724 . . . . 0.0 112.954 -178.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.629 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -110.84 -150.41 0.46 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.876 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.0 m -109.58 80.49 1.6 Allowed Pre-proline 0 CA--C 1.54 0.585 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.818 ' HG2' ' SG ' ' A' ' 26' ' ' CYS . 12.0 Cg_endo -90.59 -32.02 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.399 0 C-N-CA 123.034 2.49 . . . . 0.0 114.911 -177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 110.87 -30.31 8.18 Favored Glycine 0 C--N 1.338 0.684 0 C-N-CA 120.948 -0.644 . . . . 0.0 113.192 -179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.424 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 61.1 m 63.71 116.74 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.001 0 C-N-CA 123.638 0.775 . . . . 0.0 112.314 179.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -124.21 173.57 9.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 CA-C-N 114.858 -1.065 . . . . 0.0 108.749 178.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -76.8 81.63 3.39 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 120.949 0.404 . . . . 0.0 111.998 -178.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.524 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 125.65 -4.9 8.05 Favored Glycine 0 C--N 1.343 0.923 0 N-CA-C 115.756 1.062 . . . . 0.0 115.756 178.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.0 OUTLIER -173.62 143.61 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-N 118.749 1.275 . . . . 0.0 110.48 -178.546 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.818 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.0 OUTLIER -80.72 116.66 20.84 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-O 120.738 0.304 . . . . 0.0 110.362 177.582 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG2' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.292 0 C-N-CA 124.323 1.049 . . . . 0.0 111.8 -178.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.486 1.333 0 CA-C-O 120.375 0.131 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.459 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 0.4 OUTLIER -135.79 151.86 74.9 Favored Pre-proline 0 N--CA 1.467 0.398 0 CA-C-N 116.307 -0.406 . . . . 0.0 112.006 -179.64 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_endo -85.21 -158.25 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.642 0 C-N-CA 122.497 2.131 . . . . 0.0 113.452 179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.604 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -74.11 119.41 18.28 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 124.215 1.006 . . . . 0.0 111.446 179.574 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.414 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 101.37 37.79 3.45 Favored Glycine 0 C--N 1.332 0.306 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.538 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.441 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -124.74 13.23 7.72 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.253 -0.499 . . . . 0.0 113.803 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.463 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.4 mp 66.4 122.6 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 123.832 0.853 . . . . 0.0 109.669 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.684 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 11.1 t -143.42 -16.9 0.64 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.961 0.726 . . . . 0.0 112.961 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.419 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.2 tp -106.35 -24.04 12.37 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.507 0.194 . . . . 0.0 111.151 179.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.433 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 46.7 t -100.35 -19.48 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.969 -0.56 . . . . 0.0 112.022 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -133.96 -48.75 0.8 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 113.263 0.838 . . . . 0.0 113.263 -178.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -96.64 -163.2 1.02 Allowed 'General case' 0 N--CA 1.47 0.541 0 O-C-N 123.345 0.403 . . . . 0.0 111.357 -179.145 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.7 m -130.88 -26.02 2.23 Favored 'General case' 0 C--N 1.345 0.403 0 C-N-CA 122.542 0.337 . . . . 0.0 111.602 179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -169.94 146.42 9.96 Favored Glycine 0 C--N 1.337 0.635 0 O-C-N 123.471 0.482 . . . . 0.0 112.755 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 2.7 m -124.9 -164.69 1.3 Allowed 'General case' 0 N--CA 1.467 0.411 0 O-C-N 123.552 0.207 . . . . 0.0 110.808 179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -89.85 170.89 10.02 Favored 'General case' 0 C--N 1.346 0.447 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.726 178.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.574 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 29.8 m-20 63.35 -130.93 0.45 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 123.529 0.731 . . . . 0.0 110.759 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.584 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 22.9 t -109.98 80.89 1.9 Allowed Pre-proline 0 C--O 1.238 0.472 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.574 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 73.4 Cg_endo -92.85 95.43 0.16 Allowed 'Trans proline' 0 C--N 1.365 1.415 0 C-N-CA 122.62 2.213 . . . . 0.0 114.275 -178.23 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.516 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -70.44 -24.9 76.41 Favored Glycine 0 CA--C 1.527 0.827 0 CA-C-N 114.671 -1.15 . . . . 0.0 113.201 178.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.402 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 3.5 m 61.99 111.14 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 123.815 0.846 . . . . 0.0 111.704 179.03 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.45 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -127.41 -148.72 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 CA-C-N 115.615 -0.72 . . . . 0.0 110.551 -179.862 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.422 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 4.2 t80 -86.42 101.94 13.6 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 113.434 0.901 . . . . 0.0 113.434 -177.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.534 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.8 29.39 71.08 Favored Glycine 0 C--N 1.342 0.887 0 CA-C-N 115.252 -0.885 . . . . 0.0 114.977 177.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.534 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.3 pp -171.21 138.3 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 -179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.604 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 35.9 t -87.28 102.02 14.09 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.919 0.39 . . . . 0.0 110.479 179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.525 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.484 1.245 0 C-N-CA 123.877 0.871 . . . . 0.0 111.891 -179.204 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 N--CA 1.485 1.314 0 CA-C-O 120.346 0.117 . . . . 0.0 111.269 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -118.11 133.56 23.42 Favored Pre-proline 0 N--CA 1.474 0.768 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 178.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.42 ' HA ' ' NH1' ' A' ' 4' ' ' ARG . 22.5 Cg_exo -66.13 -162.83 0.06 OUTLIER 'Trans proline' 0 C--N 1.378 2.114 0 C-N-CA 122.876 2.384 . . . . 0.0 113.78 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.701 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -96.35 133.54 40.6 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 123.405 0.682 . . . . 0.0 110.56 -179.294 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 100.21 34.55 4.78 Favored Glycine 0 C--N 1.334 0.459 0 CA-C-N 115.481 -0.782 . . . . 0.0 111.459 -178.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.738 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -110.94 -95.81 2.33 Favored Glycine 0 C--N 1.339 0.714 0 O-C-N 123.907 0.416 . . . . 0.0 112.729 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.738 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 177.55 144.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 C-N-CA 124.26 1.024 . . . . 0.0 109.283 -179.125 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.606 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 40.7 t -158.31 -63.35 0.08 Allowed 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 179.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.8 tp -69.78 -4.39 19.73 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -97.15 -31.38 3.89 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.804 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.794 -179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.69 -42.44 0.28 Allowed 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.978 0.732 . . . . 0.0 112.978 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.49 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.99 -163.85 0.89 Allowed 'General case' 0 CA--C 1.543 0.68 0 O-C-N 123.494 0.496 . . . . 0.0 111.643 -178.67 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.49 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -129.99 -26.54 2.38 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 122.443 0.297 . . . . 0.0 111.489 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -168.3 160.35 33.85 Favored Glycine 0 C--N 1.338 0.653 0 CA-C-N 116.155 -0.475 . . . . 0.0 112.935 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.606 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.4 m -133.47 -160.2 1.03 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 122.548 0.339 . . . . 0.0 110.506 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.1 154.54 33.19 Favored 'General case' 0 C--N 1.349 0.554 0 C-N-CA 122.35 0.26 . . . . 0.0 110.45 179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.596 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.0 OUTLIER 45.22 -149.5 0.08 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 124.184 0.994 . . . . 0.0 111.932 -179.213 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.5 ' N ' HD22 ' A' ' 17' ' ' ASN . 53.1 p -106.51 87.23 2.57 Favored Pre-proline 0 CA--C 1.542 0.667 0 N-CA-C 110.051 -0.351 . . . . 0.0 110.051 179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.784 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 9.3 Cg_endo -87.15 -36.8 0.09 OUTLIER 'Trans proline' 0 C--N 1.369 1.639 0 C-N-CA 122.487 2.124 . . . . 0.0 113.669 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 107.09 -34.82 5.43 Favored Glycine 0 C--N 1.337 0.605 0 C-N-CA 120.371 -0.919 . . . . 0.0 113.376 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.472 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 80.1 m 60.82 107.33 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.28 0.632 . . . . 0.0 110.552 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -123.21 164.74 20.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.843 -178.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -69.43 83.29 0.4 Allowed 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 112.332 0.493 . . . . 0.0 112.332 -178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.58 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 127.07 -8.1 7.17 Favored Glycine 0 C--N 1.343 0.954 0 CA-C-O 118.532 -1.149 . . . . 0.0 115.808 178.11 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.58 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.4 pp -172.28 140.28 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 118.901 1.35 . . . . 0.0 110.374 -178.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 2.6 t -85.7 85.06 7.42 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-O 121.354 0.597 . . . . 0.0 109.868 177.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.784 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.249 0 C-N-CA 124.145 0.978 . . . . 0.0 111.822 -179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 51.3 t . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 120.656 0.265 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.655 HD11 HD22 ' A' ' 12' ' ' LEU . 1.1 pt -143.71 155.71 59.75 Favored Pre-proline 0 CA--C 1.54 0.588 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.31 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -84.9 -175.38 2.04 Favored 'Trans proline' 0 C--N 1.372 1.777 0 C-N-CA 122.712 2.275 . . . . 0.0 113.432 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.561 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 1.5 mpt_? -68.42 118.57 11.65 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 124.059 0.944 . . . . 0.0 111.18 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.27 32.61 4.54 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.38 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.667 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.24 42.95 1.35 Allowed Glycine 0 C--N 1.34 0.8 0 C-N-CA 121.058 -0.592 . . . . 0.0 114.093 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.828 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.1 pp 48.58 124.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 C-N-CA 125.032 1.333 . . . . 0.0 113.762 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.564 ' HA ' ' O ' ' A' ' 12' ' ' LEU . 34.5 t -143.33 -54.65 0.39 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.563 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.7 tp -72.69 -8.94 57.83 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -179.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.463 ' CG1' ' HB ' ' A' ' 7' ' ' ILE . 7.1 p -94.91 -38.7 9.24 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.779 -179.194 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -150.15 -44.23 0.13 Allowed 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.655 HD22 HD11 ' A' ' 2' ' ' ILE . 2.4 tt -97.53 73.9 2.41 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 112.357 0.502 . . . . 0.0 112.357 -177.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 t -64.35 -13.04 48.1 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -102.7 71.93 0.31 Allowed Glycine 0 C--N 1.34 0.791 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.717 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.478 ' SG ' HG13 ' A' ' 2' ' ' ILE . 2.8 t -94.15 168.63 10.81 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 122.654 0.382 . . . . 0.0 110.765 -179.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.416 ' O ' ' HG3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -87.99 169.75 11.71 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.616 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.758 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 27.1 p30 47.84 -133.0 1.33 Allowed 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 125.242 1.417 . . . . 0.0 112.874 179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 p -103.67 82.23 0.53 Allowed Pre-proline 0 N--CA 1.469 0.509 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.758 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 62.6 Cg_endo -98.1 98.92 0.07 OUTLIER 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.627 2.218 . . . . 0.0 114.089 -178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.49 -25.13 41.06 Favored Glycine 0 CA--C 1.533 1.187 0 CA-C-N 115.591 -0.731 . . . . 0.0 113.052 177.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.563 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 29.4 m 56.33 118.18 0.01 OUTLIER 'General case' 0 C--N 1.362 1.115 0 C-N-CA 124.165 0.986 . . . . 0.0 112.701 178.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.417 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.4 OUTLIER -129.6 -176.05 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.418 178.908 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.417 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -77.76 93.84 4.37 Favored 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.551 0.574 . . . . 0.0 112.551 -178.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.546 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 105.45 9.52 33.26 Favored Glycine 0 C--N 1.341 0.854 0 N-CA-C 115.864 1.106 . . . . 0.0 115.864 177.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.828 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -171.51 137.78 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-N 118.802 1.301 . . . . 0.0 111.242 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 22.1 t -75.1 99.49 3.95 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 122.798 0.439 . . . . 0.0 110.454 178.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.561 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.168 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.985 -179.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.351 0 CA-C-O 120.667 0.27 . . . . 0.0 111.139 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 15' ' ' CYS . 2.0 pt -140.71 141.62 25.55 Favored Pre-proline 0 CA--C 1.538 0.496 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.302 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 95.1 Cg_endo -83.4 172.39 10.47 Favored 'Trans proline' 0 C--N 1.368 1.567 0 C-N-CA 122.292 1.995 . . . . 0.0 113.913 179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.7 OUTLIER -52.48 118.98 3.98 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 124.782 1.233 . . . . 0.0 111.99 178.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 102.96 32.72 4.59 Favored Glycine 0 C--N 1.331 0.286 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.18 179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.456 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -123.35 16.26 8.06 Favored Glycine 0 C--N 1.337 0.62 0 C-N-CA 121.492 -0.385 . . . . 0.0 113.216 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.466 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 mp 65.88 123.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 C-N-CA 124.096 0.959 . . . . 0.0 109.806 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.475 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 12.7 t -138.44 -14.91 1.26 Allowed 'General case' 0 N--CA 1.468 0.449 0 N-CA-C 112.459 0.541 . . . . 0.0 112.459 -179.833 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.421 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -109.75 -26.13 10.01 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.466 0.174 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.411 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 50.2 t -100.32 -18.18 6.44 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.648 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.015 -178.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.43 -50.12 0.99 Allowed 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 113.067 0.765 . . . . 0.0 113.067 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.415 ' HG ' ' H ' ' A' ' 13' ' ' SER . 3.5 tp -104.04 -160.45 0.77 Allowed 'General case' 0 CA--C 1.538 0.513 0 O-C-N 123.346 0.404 . . . . 0.0 111.211 -179.126 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.415 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 13.9 t -134.28 -30.44 1.17 Allowed 'General case' 0 C--N 1.346 0.45 0 N-CA-C 111.81 0.3 . . . . 0.0 111.81 -179.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -159.45 135.1 3.99 Favored Glycine 0 C--N 1.336 0.538 0 O-C-N 123.503 0.502 . . . . 0.0 112.864 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.577 ' HB3' ' O ' ' A' ' 2' ' ' ILE . 14.7 m -97.44 -166.05 1.34 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 122.322 0.249 . . . . 0.0 111.441 -179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -84.88 -40.14 17.42 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.244 0.831 . . . . 0.0 113.244 -178.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.75 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.7 m-80 -92.1 -133.85 0.14 Allowed 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 122.546 0.338 . . . . 0.0 110.961 -179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.55 ' H ' ' NH1' ' A' ' 4' ' ' ARG . 23.2 t -98.85 88.98 0.79 Allowed Pre-proline 0 C--N 1.35 0.587 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.518 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.75 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 74.2 Cg_endo -94.25 96.74 0.13 Allowed 'Trans proline' 0 C--N 1.364 1.357 0 C-N-CA 122.318 2.012 . . . . 0.0 115.172 -178.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.502 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -67.01 -20.01 70.43 Favored Glycine 0 CA--C 1.529 0.962 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.157 175.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.465 ' HB3' ' C ' ' A' ' 8' ' ' CYS . 2.7 m 54.29 110.0 0.01 OUTLIER 'General case' 0 C--N 1.361 1.104 0 C-N-CA 124.758 1.223 . . . . 0.0 112.578 178.055 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.46 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -126.09 -148.01 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.538 -179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 5.2 t80 -86.35 100.61 12.43 Favored 'General case' 0 CA--C 1.539 0.541 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.567 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 70.91 29.42 69.19 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.212 -0.904 . . . . 0.0 115.059 177.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.567 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.5 pp -170.39 137.64 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 123.08 0.552 . . . . 0.0 110.485 -179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.696 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 26.3 t -81.25 99.79 8.8 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.335 0.654 . . . . 0.0 110.544 178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.485 1.314 0 C-N-CA 123.736 0.814 . . . . 0.0 112.137 -179.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 22.6 t . . . . . 0 N--CA 1.486 1.365 0 CA-C-O 120.3 0.095 . . . . 0.0 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -128.37 153.97 79.11 Favored Pre-proline 0 N--CA 1.468 0.473 0 O-C-N 123.348 0.405 . . . . 0.0 112.076 -179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.81 -149.73 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.87 0 C-N-CA 123.0 2.466 . . . . 0.0 112.628 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.46 ' HG3' ' OXT' ' A' ' 27' ' ' ALA . 2.4 mpt_? -88.57 124.52 34.11 Favored 'General case' 0 C--O 1.236 0.385 0 C-N-CA 123.527 0.731 . . . . 0.0 110.96 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 103.69 37.47 2.99 Favored Glycine 0 C--N 1.33 0.245 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.962 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.689 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -115.57 -97.16 2.09 Favored Glycine 0 C--N 1.335 0.525 0 O-C-N 123.802 0.354 . . . . 0.0 112.353 -179.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.689 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.8 pp 179.24 134.71 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 C-N-CA 124.332 1.053 . . . . 0.0 109.058 -179.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.49 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 35.3 t -151.9 -60.92 0.16 Allowed 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -179.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.441 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -67.72 -5.01 14.0 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 112.318 0.488 . . . . 0.0 112.318 -179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.1 p -100.1 -28.83 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.935 -179.295 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -143.6 -46.01 0.28 Allowed 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.516 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -164.6 1.01 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.798 -178.528 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.516 ' H ' HD23 ' A' ' 12' ' ' LEU . 53.1 m -133.95 -24.11 1.71 Allowed 'General case' 0 N--CA 1.466 0.373 0 C-N-CA 122.562 0.345 . . . . 0.0 111.396 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -165.1 157.99 30.66 Favored Glycine 0 C--N 1.339 0.707 0 O-C-N 123.532 0.52 . . . . 0.0 112.823 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.487 ' H ' ' HG2' ' A' ' 19' ' ' PRO . 15.9 m -133.37 -150.23 0.4 Allowed 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.53 0.332 . . . . 0.0 110.907 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 20.1 m -85.06 162.35 19.35 Favored 'General case' 0 C--N 1.347 0.483 0 C-N-CA 122.685 0.394 . . . . 0.0 111.637 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.613 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 43.47 -123.78 0.81 Allowed 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 124.432 1.093 . . . . 0.0 112.638 -179.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.496 ' H ' HD22 ' A' ' 17' ' ' ASN . 53.0 m -108.31 81.69 1.4 Allowed Pre-proline 0 C--O 1.238 0.463 0 C-N-CA 122.54 0.336 . . . . 0.0 110.338 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.613 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 65.1 Cg_endo -93.95 97.65 0.13 Allowed 'Trans proline' 0 C--N 1.366 1.477 0 C-N-CA 122.586 2.19 . . . . 0.0 113.159 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.26 -26.75 44.54 Favored Glycine 0 CA--C 1.531 1.07 0 CA-C-N 114.83 -1.077 . . . . 0.0 114.813 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.441 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 53.8 m 62.22 114.02 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 123.472 0.709 . . . . 0.0 112.14 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -129.69 167.39 25.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-N 114.726 -1.124 . . . . 0.0 108.92 178.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -71.5 90.95 1.02 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 123.96 -10.46 8.37 Favored Glycine 0 C--N 1.343 0.921 0 CA-C-O 118.857 -0.968 . . . . 0.0 115.401 178.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.1 pp -168.16 140.57 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.501 1.151 . . . . 0.0 109.878 -178.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.579 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 14.0 t -82.22 94.75 7.36 Favored 'General case' 0 C--O 1.236 0.393 0 CA-C-O 121.258 0.552 . . . . 0.0 110.764 178.984 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.46 ' OXT' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.482 1.145 0 C-N-CA 124.059 0.943 . . . . 0.0 112.064 -179.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.608 0.242 . . . . 0.0 111.181 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.414 HD11 HD13 ' A' ' 12' ' ' LEU . 0.4 OUTLIER -136.74 155.93 76.36 Favored Pre-proline 0 CA--C 1.538 0.502 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.364 179.504 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -79.34 172.56 14.43 Favored 'Trans proline' 0 C--N 1.372 1.776 0 C-N-CA 122.524 2.149 . . . . 0.0 113.86 -179.213 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.429 ' HD2' ' H ' ' A' ' 18' ' ' SER . 15.8 mtp180 -84.55 106.21 15.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.85 179.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 135.11 18.75 0.82 Allowed Glycine 0 N--CA 1.451 -0.317 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.386 -178.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.71 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -109.84 -76.82 0.91 Allowed Glycine 0 N--CA 1.444 -0.8 0 CA-C-N 114.868 -0.666 . . . . 0.0 112.293 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.71 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.9 pp 178.88 139.4 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 C-N-CA 124.2 1.0 . . . . 0.0 109.719 -179.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.476 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 28.1 t -158.7 -15.0 0.07 Allowed 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.434 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.0 tp -114.9 -16.18 11.73 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-N 118.154 0.434 . . . . 0.0 111.641 179.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 14.8 p -99.59 -26.21 3.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.77 0 O-C-N 123.477 0.486 . . . . 0.0 112.227 -178.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.9 -44.66 0.65 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 112.527 0.565 . . . . 0.0 112.527 -179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 2' ' ' ILE . 0.2 OUTLIER -94.71 -169.9 2.12 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 115.963 -0.562 . . . . 0.0 111.274 -179.228 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.9 m -130.28 -24.41 2.57 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.473 -0.33 . . . . 0.0 111.684 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -166.94 149.94 16.2 Favored Glycine 0 C--N 1.338 0.685 0 O-C-N 123.483 0.489 . . . . 0.0 112.632 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.556 ' H ' ' CG ' ' A' ' 19' ' ' PRO . 14.8 m -109.73 -167.71 1.23 Allowed 'General case' 0 CA--C 1.538 0.519 0 O-C-N 123.55 0.206 . . . . 0.0 111.166 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -84.54 -38.92 19.42 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -178.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.747 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 70.0 m-80 -93.33 -132.27 0.14 Allowed 'General case' 0 N--CA 1.475 0.776 0 O-C-N 123.237 0.335 . . . . 0.0 110.827 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.429 ' H ' ' HD2' ' A' ' 4' ' ' ARG . 52.7 m -98.24 88.52 0.67 Allowed Pre-proline 0 C--N 1.348 0.541 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.747 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 38.3 Cg_endo -91.7 96.34 0.21 Allowed 'Trans proline' 0 C--N 1.362 1.262 0 C-N-CA 122.312 2.008 . . . . 0.0 114.775 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.501 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -64.48 -23.59 68.68 Favored Glycine 0 CA--C 1.528 0.894 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.29 175.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.434 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 3.2 m 53.1 109.11 0.01 OUTLIER 'General case' 0 C--N 1.361 1.074 0 C-N-CA 124.94 1.296 . . . . 0.0 112.936 178.041 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.49 HD11 ' O ' ' A' ' 27' ' ' ALA . 0.8 OUTLIER -125.83 -176.27 1.39 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-N 114.648 -1.16 . . . . 0.0 108.948 178.952 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.477 ' H ' HG22 ' A' ' 22' ' ' ILE . 10.7 t80 -78.89 94.37 5.19 Favored 'General case' 0 CA--C 1.54 0.593 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -178.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.477 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 113.17 -6.7 25.18 Favored Glycine 0 C--N 1.342 0.914 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 177.892 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.562 ' HA ' ' O ' ' A' ' 6' ' ' GLY . 1.3 pp -163.76 144.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.688 1.244 . . . . 0.0 111.955 -178.198 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.642 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 37.7 t -72.23 105.23 3.94 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 122.8 0.44 . . . . 0.0 110.033 176.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.501 ' HB2' ' H ' ' A' ' 20' ' ' GLY . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.059 -0.972 . . . . 0.0 112.044 -178.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.329 0 CA-C-O 120.6 0.238 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.4 148.37 65.77 Favored Pre-proline 0 CA--C 1.539 0.55 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.412 179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -80.93 -150.91 0.04 OUTLIER 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.914 2.409 . . . . 0.0 113.439 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.539 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 4.3 mpt_? -90.26 126.74 35.94 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 123.496 0.719 . . . . 0.0 110.646 -179.48 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 97.66 45.44 2.49 Favored Glycine 0 C--N 1.334 0.436 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.779 -179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.674 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -123.38 -95.08 1.17 Allowed Glycine 0 C--N 1.337 0.608 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.708 -179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.674 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.7 pp 175.43 141.19 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 C-N-CA 124.507 1.123 . . . . 0.0 109.223 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 53.8 t -156.47 -72.44 0.1 Allowed 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 112.046 0.388 . . . . 0.0 112.046 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.471 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.3 tp -59.99 -6.15 1.24 Allowed 'General case' 0 N--CA 1.487 1.379 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 8.9 p -86.31 -33.16 7.08 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 CA-C-N 115.903 -0.59 . . . . 0.0 111.297 179.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -148.69 -44.77 0.15 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 -179.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.416 ' HG ' ' H ' ' A' ' 13' ' ' SER . 0.6 OUTLIER -88.5 -174.23 4.49 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.307 -178.321 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.416 ' H ' ' HG ' ' A' ' 12' ' ' LEU . 45.2 m -156.74 -28.33 0.09 Allowed 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 124.109 0.963 . . . . 0.0 109.661 179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -88.46 70.85 2.56 Favored Glycine 0 C--N 1.342 0.891 0 CA-C-N 115.099 -0.955 . . . . 0.0 112.171 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.452 ' HB2' ' SG ' ' A' ' 8' ' ' CYS . 6.9 t -90.22 159.48 16.69 Favored 'General case' 0 C--O 1.235 0.331 0 C-N-CA 122.898 0.479 . . . . 0.0 111.164 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -81.15 156.08 25.9 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.548 179.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.403 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 22.5 p30 47.77 -150.86 0.12 Allowed 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 124.117 0.967 . . . . 0.0 112.0 -179.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 52.8 m -117.43 77.38 10.27 Favored Pre-proline 0 CA--C 1.539 0.545 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.75 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.6 Cg_endo -87.15 -38.58 0.08 OUTLIER 'Trans proline' 0 C--N 1.366 1.476 0 C-N-CA 122.673 2.248 . . . . 0.0 113.915 -178.57 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 119.14 -33.25 4.79 Favored Glycine 0 C--N 1.339 0.738 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.68 -179.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.471 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 79.9 m 60.59 107.09 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 123.415 0.686 . . . . 0.0 110.931 -178.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -124.78 163.16 25.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.493 -179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -70.9 80.57 0.64 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.022 0.439 . . . . 0.0 111.854 -178.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.542 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 134.65 -13.23 4.52 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-O 118.596 -1.113 . . . . 0.0 115.416 178.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.542 HG23 ' O ' ' A' ' 24' ' ' GLY . 1.1 pp -173.57 140.93 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.248 0 CA-C-N 118.788 1.294 . . . . 0.0 110.277 -178.707 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.676 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -84.05 83.14 8.06 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-O 121.5 0.667 . . . . 0.0 110.077 177.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.75 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.233 0 C-N-CA 124.261 1.024 . . . . 0.0 112.066 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 43.9 t . . . . . 0 N--CA 1.485 1.32 0 CA-C-O 120.721 0.296 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.628 HG13 ' SG ' ' A' ' 15' ' ' CYS . 1.5 pt -150.21 157.14 37.47 Favored Pre-proline 0 CA--C 1.542 0.644 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.045 179.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -80.0 -173.05 1.7 Allowed 'Trans proline' 0 C--N 1.375 1.922 0 C-N-CA 122.64 2.227 . . . . 0.0 113.389 -179.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.624 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 1.9 mpt_? -72.5 122.26 21.0 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.828 0.851 . . . . 0.0 110.949 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.547 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 99.71 36.49 4.26 Favored Glycine 0 C--N 1.332 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.347 -179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.488 ' H ' ' H ' ' A' ' 26' ' ' CYS . . . -129.66 17.05 5.55 Favored Glycine 0 C--N 1.339 0.744 0 C-N-CA 121.53 -0.367 . . . . 0.0 113.478 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.627 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.7 mp 66.31 126.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 124.212 1.005 . . . . 0.0 109.892 179.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.551 ' SG ' ' HB2' ' A' ' 15' ' ' CYS . 13.8 t -142.4 -10.38 0.84 Allowed 'General case' 0 CA--C 1.543 0.693 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.3 tt -118.27 -22.87 7.5 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 117.683 0.22 . . . . 0.0 111.111 179.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 41.7 t -100.05 -18.39 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.553 0 O-C-N 123.52 0.512 . . . . 0.0 111.409 -178.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -131.27 -45.19 1.01 Allowed 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -179.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -104.39 -170.23 1.74 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.379 -179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 53.4 m -148.45 -24.24 0.33 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.083 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -129.94 93.96 0.33 Allowed Glycine 0 C--N 1.34 0.781 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.488 179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.628 ' SG ' HG13 ' A' ' 2' ' ' ILE . 5.5 t -99.36 168.6 9.91 Favored 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 122.847 0.459 . . . . 0.0 110.239 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.32 164.15 15.03 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.677 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 80.2 m-20 64.9 -135.25 0.24 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 124.185 0.994 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.0 m -107.96 78.69 0.79 Allowed Pre-proline 0 C--O 1.238 0.475 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.677 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 55.3 Cg_endo -96.44 99.88 0.09 OUTLIER 'Trans proline' 0 C--N 1.361 1.225 0 C-N-CA 122.614 2.209 . . . . 0.0 114.984 -177.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -61.18 -21.42 59.46 Favored Glycine 0 CA--C 1.534 1.27 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.58 176.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 4.0 m 55.46 106.52 0.01 OUTLIER 'General case' 0 C--N 1.363 1.186 0 C-N-CA 124.366 1.066 . . . . 0.0 111.363 179.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.07 -148.69 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.907 -179.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.421 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.6 t80 -85.69 100.27 11.88 Favored 'General case' 0 CA--C 1.539 0.555 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -178.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.508 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 74.4 25.84 69.51 Favored Glycine 0 C--N 1.341 0.83 0 CA-C-N 115.212 -0.903 . . . . 0.0 115.214 177.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.627 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -167.63 137.07 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 117.267 0.534 . . . . 0.0 111.073 -179.737 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 14.7 t -79.16 91.22 4.92 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.251 0.62 . . . . 0.0 109.765 178.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.556 ' HB2' ' HA ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.484 1.274 0 C-N-CA 123.857 0.863 . . . . 0.0 111.682 -178.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.6 m . . . . . 0 N--CA 1.487 1.4 0 CA-C-O 120.662 0.268 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.71 HD12 ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -111.27 144.75 31.12 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.336 -179.761 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -80.76 177.42 8.04 Favored 'Trans proline' 0 C--N 1.374 1.902 0 C-N-CA 122.458 2.105 . . . . 0.0 113.42 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.607 ' HG3' ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -77.26 124.55 28.0 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 123.923 0.889 . . . . 0.0 110.965 179.536 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.54 ' HA2' HG22 ' A' ' 25' ' ' ILE . . . 104.06 32.1 4.49 Favored Glycine 0 N--CA 1.451 -0.351 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.822 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.442 ' C ' HD12 ' A' ' 7' ' ' ILE . . . -122.82 14.51 8.51 Favored Glycine 0 C--N 1.34 0.776 0 C-N-CA 121.551 -0.357 . . . . 0.0 113.551 -179.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.509 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 3.3 mp 67.58 128.15 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 C-N-CA 123.944 0.897 . . . . 0.0 109.979 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HA ' ' CB ' ' A' ' 12' ' ' LEU . 12.7 t -146.15 -14.89 0.46 Allowed 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 112.467 0.543 . . . . 0.0 112.467 -179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.408 ' HB3' ' O ' ' A' ' 22' ' ' ILE . 4.3 tp -110.99 -24.58 10.28 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 111.374 0.139 . . . . 0.0 111.374 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.441 ' CG2' ' H ' ' A' ' 24' ' ' GLY . 47.5 t -100.41 -22.24 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -178.362 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -135.03 -47.72 0.73 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -179.075 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.483 ' HB2' ' O ' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -92.32 -168.74 2.05 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.922 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.2 m -127.64 -34.99 2.16 Favored 'General case' 0 C--O 1.235 0.307 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -179.26 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.435 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -163.82 153.56 24.02 Favored Glycine 0 C--N 1.334 0.422 0 O-C-N 123.546 0.529 . . . . 0.0 113.042 -179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' SG ' HD12 ' A' ' 2' ' ' ILE . 12.5 m -126.65 -156.32 0.74 Allowed 'General case' 0 CA--C 1.542 0.654 0 O-C-N 123.736 0.316 . . . . 0.0 110.607 179.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.8 t -86.12 166.24 15.95 Favored 'General case' 0 N--CA 1.469 0.476 0 C-N-CA 123.129 0.572 . . . . 0.0 111.225 -179.977 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.617 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 1.1 p-10 45.08 -126.3 1.12 Allowed 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 124.421 1.089 . . . . 0.0 112.629 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.474 ' H ' HD22 ' A' ' 17' ' ' ASN . 53.1 m -108.53 81.39 1.39 Allowed Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 122.477 0.311 . . . . 0.0 110.949 179.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.617 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 57.9 Cg_endo -94.73 98.58 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.427 0 C-N-CA 122.648 2.232 . . . . 0.0 112.707 179.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -55.93 -29.9 56.09 Favored Glycine 0 N--CA 1.471 1.025 0 CA-C-N 114.82 -1.082 . . . . 0.0 115.211 -179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 3.9 m 62.83 109.08 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 117.741 0.771 . . . . 0.0 111.157 179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.443 HD11 ' OXT' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -125.41 -147.73 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.932 -179.249 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.432 ' HA ' ' CG2' ' A' ' 10' ' ' VAL . 5.1 t80 -85.36 101.3 12.46 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.539 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 69.7 29.95 70.94 Favored Glycine 0 C--N 1.342 0.912 0 CA-C-N 115.179 -0.918 . . . . 0.0 115.048 177.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.54 HG22 ' HA2' ' A' ' 5' ' ' GLY . 1.4 pp -170.52 138.07 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.219 0.608 . . . . 0.0 109.44 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.486 ' SG ' ' HB2' ' A' ' 19' ' ' PRO . 43.9 t -85.29 102.33 13.28 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 121.056 0.455 . . . . 0.0 110.649 179.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.607 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.058 0.943 . . . . 0.0 112.103 -179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 11.2 t . . . . . 0 N--CA 1.486 1.352 0 CA-C-O 120.739 0.304 . . . . 0.0 111.002 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.476 HD11 ' O ' ' A' ' 7' ' ' ILE . 0.3 OUTLIER -163.12 147.29 8.88 Favored Pre-proline 0 N--CA 1.466 0.336 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.13 179.138 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -81.38 161.31 19.88 Favored 'Trans proline' 0 C--N 1.367 1.515 0 C-N-CA 122.124 1.883 . . . . 0.0 112.796 178.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.532 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 2.4 tmm_? -44.16 118.39 1.48 Allowed 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.417 1.087 . . . . 0.0 111.907 178.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 116.09 25.91 3.41 Favored Glycine 0 C--N 1.331 0.293 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.887 -179.712 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.657 ' O ' HG23 ' A' ' 7' ' ' ILE . . . -112.79 -100.68 2.48 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 114.896 -0.652 . . . . 0.0 112.738 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.657 HG23 ' O ' ' A' ' 6' ' ' GLY . 1.6 pp 179.28 133.97 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.393 0 C-N-CA 124.139 0.976 . . . . 0.0 109.388 -179.177 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.658 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 29.1 t -150.43 -49.88 0.13 Allowed 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.485 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 2.6 tp -78.21 0.31 25.6 Favored 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.5 p -100.12 -35.89 4.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -140.48 -39.2 0.43 Allowed 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 113.041 0.756 . . . . 0.0 113.041 -178.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.487 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.97 -165.76 1.29 Allowed 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.651 -178.78 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.487 ' H ' HD23 ' A' ' 12' ' ' LEU . 16.1 t -131.08 -24.89 2.3 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 122.505 0.322 . . . . 0.0 110.962 179.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -174.74 147.76 9.29 Favored Glycine 0 C--N 1.337 0.605 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.267 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.658 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 3.3 m -115.74 -154.66 0.55 Allowed 'General case' 0 CA--C 1.535 0.383 0 O-C-N 123.49 0.171 . . . . 0.0 111.012 -179.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -92.06 171.77 8.88 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -179.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.618 ' ND2' ' H ' ' A' ' 18' ' ' SER . 1.9 p-10 44.01 -88.82 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 125.653 1.581 . . . . 0.0 114.455 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.618 ' H ' ' ND2' ' A' ' 17' ' ' ASN . 53.0 m -129.72 84.73 60.36 Favored Pre-proline 0 N--CA 1.468 0.466 0 C-N-CA 122.442 0.297 . . . . 0.0 110.923 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.474 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 54.0 Cg_endo -94.98 93.5 0.11 Allowed 'Trans proline' 0 C--N 1.365 1.395 0 C-N-CA 122.632 2.221 . . . . 0.0 114.113 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.415 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.77 -25.77 74.96 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.45 178.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.485 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 22.8 m 56.93 109.99 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 124.367 1.067 . . . . 0.0 112.753 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.618 HD12 HD13 ' A' ' 25' ' ' ILE . 0.8 OUTLIER -131.18 165.14 32.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.466 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.457 178.866 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 11.1 t80 -71.02 92.66 0.95 Allowed 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 117.88 -4.88 16.45 Favored Glycine 0 C--N 1.341 0.828 0 CA-C-O 118.95 -0.916 . . . . 0.0 115.248 178.341 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.618 HD13 HD12 ' A' ' 22' ' ' ILE . 0.9 OUTLIER -171.85 138.5 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 118.427 1.114 . . . . 0.0 110.011 -179.073 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' O ' ' HA ' ' A' ' 4' ' ' ARG . 13.2 t -78.75 122.93 26.65 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.433 179.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.537 ' O ' HD11 ' A' ' 22' ' ' ILE . . . . . . . . 0 N--CA 1.484 1.244 0 CA-C-O 118.17 -0.919 . . . . 0.0 111.983 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 120.435 0.159 . . . . 0.0 110.683 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -132.42 156.72 79.77 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.792 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -77.99 -146.4 0.03 OUTLIER 'Trans proline' 0 C--N 1.372 1.808 0 C-N-CA 122.565 2.176 . . . . 0.0 111.424 178.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.615 ' HD3' ' O ' ' A' ' 18' ' ' SER . 53.1 mtm180 -108.13 127.79 54.12 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-O 121.068 0.461 . . . . 0.0 110.879 179.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.95 18.51 6.83 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 114.75 -1.114 . . . . 0.0 111.653 -178.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.555 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.17 56.11 0.75 Allowed Glycine 0 C--N 1.344 0.981 0 C-N-CA 121.31 -0.471 . . . . 0.0 114.017 -179.102 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.773 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.2 pp 43.89 122.53 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 C-N-CA 125.606 1.562 . . . . 0.0 114.759 178.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.73 ' HB2' ' SG ' ' A' ' 15' ' ' CYS . 25.4 t -143.67 -16.86 0.62 Allowed 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.98 0.733 . . . . 0.0 112.98 179.461 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.8 tp -113.16 -14.01 12.94 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.581 0.229 . . . . 0.0 111.286 179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 9.9 p -94.09 -31.65 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.82 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.019 -178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.669 ' HB3' HD13 ' A' ' 7' ' ' ILE . . . -136.61 -46.07 0.6 Allowed 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 112.37 0.507 . . . . 0.0 112.37 -179.514 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -85.0 -173.09 4.54 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.286 -179.241 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 14.5 t -126.5 -28.2 3.07 Favored 'General case' 0 C--O 1.235 0.337 0 O-C-N 123.242 0.339 . . . . 0.0 111.56 -179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.433 ' HA2' ' SG ' ' A' ' 8' ' ' CYS . . . -166.05 154.97 25.92 Favored Glycine 0 C--N 1.335 0.519 0 C-N-CA 121.246 -0.502 . . . . 0.0 113.237 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.73 ' SG ' ' HB2' ' A' ' 8' ' ' CYS . 1.6 m -130.28 -164.75 1.45 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 122.677 0.391 . . . . 0.0 110.255 179.713 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.4 m -92.68 170.06 10.01 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.095 177.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.576 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 37.2 m-20 63.56 -131.37 0.43 Allowed 'General case' 0 N--CA 1.491 1.578 0 C-N-CA 123.349 0.66 . . . . 0.0 110.673 -179.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.615 ' O ' ' HD3' ' A' ' 4' ' ' ARG . 52.8 m -110.92 79.68 1.97 Allowed Pre-proline 0 CA--C 1.537 0.443 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.632 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.576 ' HD3' ' O ' ' A' ' 17' ' ' ASN . 18.1 Cg_endo -89.92 96.44 0.3 Allowed 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.775 2.316 . . . . 0.0 113.59 -178.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -67.31 -24.65 73.59 Favored Glycine 0 CA--C 1.528 0.85 0 CA-C-N 114.87 -1.059 . . . . 0.0 112.642 178.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.45 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 4.0 m 58.39 111.89 0.01 OUTLIER 'General case' 0 C--N 1.36 1.045 0 C-N-CA 124.008 0.923 . . . . 0.0 112.328 178.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.437 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.9 OUTLIER -124.83 174.13 9.52 Favored 'Isoleucine or valine' 0 C--O 1.237 0.395 0 CA-C-N 114.656 -1.156 . . . . 0.0 109.026 179.244 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.437 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.3 t80 -73.59 93.28 2.02 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -178.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 116.27 -2.52 20.62 Favored Glycine 0 C--N 1.343 0.967 0 N-CA-C 115.879 1.111 . . . . 0.0 115.879 177.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.773 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.4 pp -170.75 143.37 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.073 0 CA-C-N 118.726 1.263 . . . . 0.0 110.593 -178.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.532 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 40.7 t -78.58 61.47 2.93 Favored 'General case' 0 CA--C 1.541 0.617 0 CA-C-O 121.263 0.554 . . . . 0.0 110.131 177.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.494 ' OXT' ' HB3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.222 0 C-N-CA 124.174 0.99 . . . . 0.0 111.69 -179.235 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.3 m . . . . . 0 N--CA 1.486 1.33 0 CA-C-O 120.496 0.188 . . . . 0.0 111.327 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.526 HG13 ' SG ' ' A' ' 15' ' ' CYS . 5.3 pt -115.43 125.56 28.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.403 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 2' ' ' ILE . 8.3 Cg_exo -72.31 172.71 14.37 Favored 'Trans proline' 0 C--N 1.373 1.839 0 C-N-CA 122.753 2.302 . . . . 0.0 113.798 -179.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.583 ' NH1' ' HB3' ' A' ' 18' ' ' SER . 0.0 OUTLIER -56.17 120.48 7.61 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 124.376 1.07 . . . . 0.0 111.824 179.427 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.6 29.08 5.47 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.844 -179.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.498 ' H ' ' HB3' ' A' ' 26' ' ' CYS . . . -130.13 46.75 1.06 Allowed Glycine 0 C--N 1.34 0.805 0 C-N-CA 121.135 -0.555 . . . . 0.0 113.924 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.747 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.8 pp 45.09 130.6 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 C-N-CA 125.364 1.466 . . . . 0.0 114.649 178.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.406 ' C ' ' HB3' ' A' ' 21' ' ' CYS . 39.5 t -152.96 -9.01 0.17 Allowed 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 113.33 0.863 . . . . 0.0 113.33 179.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.467 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 3.9 tp -122.42 -13.78 7.97 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 117.95 0.341 . . . . 0.0 111.17 179.287 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . . . . . . . . . 7.1 p -88.86 -36.25 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.652 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -138.14 -40.81 0.53 Allowed 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.037 -0.528 . . . . 0.0 112.081 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -89.4 179.24 6.12 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.967 -178.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 52.6 m -150.73 -4.99 0.31 Allowed 'General case' 0 C--O 1.237 0.435 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.098 179.122 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -133.41 107.5 0.69 Allowed Glycine 0 C--N 1.345 1.035 0 CA-C-N 116.048 -0.524 . . . . 0.0 112.995 -179.375 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.526 ' SG ' HG13 ' A' ' 2' ' ' ILE . 12.0 t -128.29 162.46 26.99 Favored 'General case' 0 C--O 1.237 0.409 0 C-N-CA 122.948 0.499 . . . . 0.0 109.816 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 94.2 m -99.28 164.67 12.03 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -178.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.631 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 76.7 m-20 75.84 -128.91 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 124.956 1.302 . . . . 0.0 110.533 -179.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.583 ' HB3' ' NH1' ' A' ' 4' ' ' ARG . 22.8 t -110.85 76.73 1.25 Allowed Pre-proline 0 C--O 1.239 0.514 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.762 ' HB3' ' SG ' ' A' ' 26' ' ' CYS . 30.4 Cg_endo -94.91 97.94 0.11 Allowed 'Trans proline' 0 C--N 1.364 1.384 0 C-N-CA 122.574 2.183 . . . . 0.0 115.272 -177.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.503 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -68.75 -16.3 69.92 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.878 176.076 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.467 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 8.4 m 53.58 105.89 0.01 OUTLIER 'General case' 0 C--N 1.364 1.22 0 C-N-CA 124.53 1.132 . . . . 0.0 112.352 178.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . 0.457 HG22 ' H ' ' A' ' 23' ' ' PHE . 0.8 OUTLIER -120.22 175.85 4.1 Favored 'Isoleucine or valine' 0 C--O 1.236 0.377 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.283 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.457 ' H ' HG22 ' A' ' 22' ' ' ILE . 9.4 t80 -73.58 91.84 1.87 Allowed 'General case' 0 CA--C 1.541 0.624 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -178.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.588 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 112.84 6.14 23.18 Favored Glycine 0 C--N 1.343 0.945 0 CA-C-O 118.526 -1.152 . . . . 0.0 115.925 177.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.747 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.3 pp -175.07 139.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 CA-C-N 118.881 1.34 . . . . 0.0 111.594 -179.108 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.762 ' SG ' ' HB3' ' A' ' 19' ' ' PRO . 7.5 t -74.48 94.07 2.55 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 122.822 0.449 . . . . 0.0 109.852 176.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.523 ' HB3' ' HG3' ' A' ' 4' ' ' ARG . . . . . . . . 0 N--CA 1.483 1.188 0 CA-C-O 118.051 -0.976 . . . . 0.0 111.886 -179.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.485 1.299 0 CA-C-O 120.659 0.266 . . . . 0.0 111.273 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 1.7 pt -141.44 140.61 20.87 Favored Pre-proline 0 CA--C 1.541 0.616 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.795 179.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -80.2 -171.29 1.21 Allowed 'Trans proline' 0 C--N 1.374 1.905 0 C-N-CA 122.644 2.229 . . . . 0.0 113.277 -179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.516 ' HA ' ' O ' ' A' ' 26' ' ' CYS . 0.4 OUTLIER -66.4 113.2 4.48 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 123.756 0.822 . . . . 0.0 111.117 179.6 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 101.07 45.67 1.84 Allowed Glycine 0 C--N 1.334 0.427 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.137 -179.411 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.587 ' O ' HG13 ' A' ' 7' ' ' ILE . . . -130.04 38.43 1.98 Allowed Glycine 0 C--N 1.34 0.778 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.853 -179.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.74 ' H ' ' HA ' ' A' ' 25' ' ' ILE . 2.3 pp 45.5 125.28 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 C-N-CA 125.275 1.43 . . . . 0.0 113.64 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.506 ' HB2' ' SG ' ' A' ' 26' ' ' CYS . 43.3 t -141.06 -73.05 0.34 Allowed 'General case' 0 N--CA 1.464 0.242 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.426 ' HB2' ' C ' ' A' ' 21' ' ' CYS . 4.1 tp -60.02 -3.48 0.58 Allowed 'General case' 0 N--CA 1.485 1.28 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.048 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' VAL . . . . . 0.616 HG11 ' HA2' ' A' ' 24' ' ' GLY . 8.0 p -98.27 -35.7 5.29 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 CA-C-N 116.011 -0.541 . . . . 0.0 111.179 179.766 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -141.4 -47.85 0.39 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 -179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.483 HD23 ' H ' ' A' ' 13' ' ' SER . 0.2 OUTLIER -84.89 -173.12 4.55 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.943 -178.28 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.483 ' H ' HD23 ' A' ' 12' ' ' LEU . 31.9 p -160.31 -20.49 0.06 Allowed 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 123.398 0.679 . . . . 0.0 110.58 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . -112.26 97.79 0.93 Allowed Glycine 0 C--N 1.338 0.666 0 O-C-N 123.664 0.602 . . . . 0.0 113.349 -179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.08 174.42 7.24 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 178.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.3 t -82.4 -39.87 22.06 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 112.849 0.685 . . . . 0.0 112.849 -178.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . 0.563 ' O ' ' HD3' ' A' ' 19' ' ' PRO . 0.5 OUTLIER -116.0 -148.47 0.43 Allowed 'General case' 0 CA--C 1.543 0.694 0 O-C-N 123.65 0.594 . . . . 0.0 110.815 -179.348 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 53.3 m -113.27 78.27 3.27 Favored Pre-proline 0 C--O 1.238 0.48 0 N-CA-C 108.485 -0.931 . . . . 0.0 108.485 179.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.681 ' O ' ' HB2' ' A' ' 27' ' ' ALA . 10.8 Cg_endo -87.95 -36.7 0.08 OUTLIER 'Trans proline' 0 C--N 1.363 1.328 0 C-N-CA 122.889 2.393 . . . . 0.0 114.257 -177.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.85 -31.16 5.82 Favored Glycine 0 C--N 1.336 0.533 0 C-N-CA 120.557 -0.83 . . . . 0.0 113.026 -178.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . 0.426 ' C ' ' HB2' ' A' ' 9' ' ' LEU . 96.9 m 60.09 105.41 0.02 OUTLIER 'General case' 0 C--N 1.357 0.914 0 C-N-CA 123.495 0.718 . . . . 0.0 110.974 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -125.54 -175.04 1.12 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.371 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.18 -179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . . . . . . . . . 9.1 t80 -74.11 95.19 2.52 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 112.947 0.721 . . . . 0.0 112.947 -178.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.693 ' O ' HG23 ' A' ' 25' ' ' ILE . . . 91.95 21.67 32.67 Favored Glycine 0 C--N 1.34 0.779 0 CA-C-O 118.349 -1.251 . . . . 0.0 116.082 177.151 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.74 ' HA ' ' H ' ' A' ' 7' ' ' ILE . 1.5 pp -179.34 137.07 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 CA-C-N 118.778 1.289 . . . . 0.0 111.295 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.653 ' SG ' ' HG2' ' A' ' 19' ' ' PRO . 0.1 OUTLIER -85.86 69.66 10.59 Favored 'General case' 0 CA--C 1.542 0.644 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 176.453 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.681 ' HB2' ' O ' ' A' ' 19' ' ' PRO . . . . . . . . 0 N--CA 1.486 1.363 0 C-N-CA 124.719 1.208 . . . . 0.0 111.534 -178.35 . . . . . . . . 1 1 . 1 stop_ save_